aid to governmentthe profession

the public1904 to 2011

In This Issue. . . .Legal Briefs:School Gets In Your Facebook

208

Association News:NABP PMP InterConnect Steering Committee Finalizes Governance Structure and Policies

211

Association News:Counterfeit Drugs Distributed Via Internet Endanger Unsuspecting Patients

212

Association News:Boards Report 846 Disciplinary Actions in Third Quarter

213

Association News:ACPE-Accredited Providers Participate in CPE Monitor Pilot, Begin to Require NABP e-Profile ID for CPE Credit Submission

215

November-December 2011 / Volume 40 Number 10

GreyGrey: Black Process 70%

Black: Process 100K

TM

newsletterNational Association of Boards of Pharmacy®

NABP Newsle

tter

Celebratin

g

75 Years

Board of Pharmacy Executive Officers Share Successes, Challenges at Interactive Forum

Thirty-one executive of-ficers gathered at the Inter-active Executive Officer Fo-rum, held September 21-22, 2011, to discuss with their colleagues the challenges their boards face on a daily basis. The second in a series of three meetings themed “Prescription for Shared Future: The Partnering Plan to Protect Public Health through AWARxEness,” the Forum for executive officers reinforced the partnership between the boards of phar-macy and NABP, and the shared mission to protect public health.

Following the success of the Interactive Member Forum, which was held for the members of the boards of pharmacy in 2010, the Interactive Executive Of-ficer Forum featured panel discussions on topics of high interest to participants, as well as plenty of attendee discussion time on these

and other topics suggested dur-ing the course of the meeting. In each discussion, executive officers gained valuable new ideas as fel-low participants posed challeng-ing questions and offered a variety of relevant experi-ences, perspectives, and information. To ensure adequate discus-sion time, and in response to suggestions made by at-tendees from the Interactive Member Forum, the length of the meeting was increased from one day to two days.

The meeting kicked off with William T. Winsley, MS, RPh, chairperson, NABP Executive Commit-tee, welcoming executive officers and reiterating the purpose of the meet-ing. Winsley stressed the

importance of this unique opportunity for board of pharmacy executive officers to discuss with their col-leagues – in closed sessions – important and timely issues related to pharmacy regula-tion. He added that NABP takes seriously its role of assisting the boards of phar-macy, and that this meeting, as well as the forums for the members and compliance officers, is just one of the many ways that the Associa-

(continued on page 206)

Upcoming EventsDecember 1-2, 2011 NABP Interactive Compliance Officer Forum NABP Headquarters

January 24-25, 2012 Task Force to Review Recommendations to the Controlled Substances ActNABP Headquarters

February 29, 2012 Committee on Law Enforcement/Legislation NABP Headquarters

fromNABP

Attendees had the opportunity to network with their peers during the NABP Interactive Executive Officer Forum.

nabp newsletter

206

Attendees Network with Fellow Executive Officers, Tour NABP HeadquartersFollowing the Wednesday, September 21, 2011 session, attendees of the Interactive Executive Officer Forum visited NABP Headquarters where they had the chance to network with fellow board of pharmacy executive officers, learn of the various NABP programs and services, and tour the Association Headquarters in Mount Prospect, IL.

Executive Officer Forum

The NABP Newsletter (ISSN 8756-4483) is published 10 times a year by the National

Association of Boards of Pharmacy® (NABP®) to educate, to inform,

and to communicate the objectives and programs of the Association and its 64 member boards

of pharmacy to the profession and the

public. The opinions and views expressed in this publication do not necessarily reflect the

official views, opinions, or policies of NABP or any board unless

expressly so stated. The subscription rate is

$35 per year.

National Association of Boards of Pharmacy

1600 Feehanville Drive Mount Prospect, IL

60056 847/391-4406 www.nabp.net

custserv@nabp.net

Carmen A. Catizone Executive Director/

Secretary

Larissa Doucette Communications

Manager

©2011 National Association of Boards

of Pharmacy. All rights reserved. No part of this publication may be reproduced in any manner without the

written permission of the executive director/

secretary of the National Association of

Boards of Pharmacy.

tion strives to support and create value for the boards.

The first session of the day – “Is This the Practice of Pharmacy?” – covered four areas of pharmacy where the practice or regulation of pharmacy is being infringed upon or public safety is at risk. These areas included pill mills, regulation of pharmacy benefit managers, Internet pharmacy, and the Federal Trade Commission law suit against the North Carolina Board of Dentistry. Throughout the meeting, scheduled topics were intro-duced by board of pharmacy executive officers who had noteworthy experiences with a particular topic. After the brief overview by the panel-ist, attendees engaged in lively discussions regarding issues in their states.

At the conclusion of the first afternoon’s program-ming, attendees were taken to NABP Headquarters for a tour of the building, staff presentations, and a net-

Executive Officer Forum(continued from page 205)

working dinner. Prior to the dinner, NABP President Malcolm J. Broussard, RPh, welcomed the attendees and sought input on the progress of the meeting.

The Forum continued on Thursday morning with more networking events and programming. “Technol-ogy: Progress or Problems” was the first topic of discus-sion, and attendees focused on the areas of automated dispensing systems, virtual wholesale distributors, and uses for the NABP PMP InterConnectSM. Again, short introductions pro-vided by executive officers were followed by audience discussions. The next ses-sion, entitled “Shared State Topics,” featured topics that were suggested by execu-tive officers in response to a survey that was sent prior to the event. The topics covered included dwin-dling board of pharmacy resources: challenges for chief administrative officers, prescriber dispensing, and pharmacy robberies. In the time remaining, attendees

began discussing some of the topics that were suggested by attendees during Winsley’s welcome remarks the previ-ous day, including pharma-cists practicing in locations without pharmacy permits, dealing with errors, drug take-back programs and the potential for diversion, remote pharmacy practice, compounding regulations, immunization programs, and group purchasing using charitable exemptions.

The final session of the meeting was “Social Media: Life in 140 Characters or Less.” This session focused on executive officers’ experi-ences with social media and how it has or has not worked for their boards of pharma-cy. The session also included time to finish discussion of the additional topics that were brought up by attend-ees at the beginning of the meeting.

NABP President-elect Michael Burleson, RPh, closed the meeting with some additional informa-tion about NABP programs

(continued on page 210)

november-december 2011

207

Feature News

Executive CommitteeWilliam T. Winsley ChairpersonOne-year term

Malcolm J. BroussardPresidentOne-year term

Michael A. BurlesonPresident-electOne-year term

Karen M. RyleTreasurerOne-year term

James T. DeVitaMember, District 1Serving second year of a three-year term

Edward G. McGinleyMember, District 2Serving second year of a three-year term

Mark T. ConradiMember, District 3Serving first year of a three-year term

William J. CoverMember, District 4Serving first year of a three-year term

Lloyd K. JessenMember, District 5Serving second year of a three-year term

Joseph L. “Joe” AdamsMember, District 6Serving third year of a three-year term

Cathryn J. LewMember, District 7Serving third year of a three-year term

Hal WandMember, District 8Serving first year of a three-year term

NABP Executive Committee elections are held each year at the Association’s Annual Meeting.

FDA to Release Guidance Document on Approval Pathway for Biosimilars

Food and Drug Admin-istration (FDA) continues the process of developing an approval pathway for biosimilars, the generic equivalent of biologic drug products. The agency plans to release a draft guidance for applicants initiating biosimilar development programs by the end of 2011. Once an approval process is implemented, biosimilars may potentially increase the availability of biologic drug therapies to more patients. Further, the Biologics Price Com-petition and Innovation (BPCI) Act of 2009 al-lows for drug makers to meet a “higher standard of similarity to a reference product –‘interchange-ability.’” For drugs deemed by FDA to be interchange-able, pharmacists will be allowed to make “substitu-tions between biologics without the prescriber’s intervention.” To meet this higher standard, FDA explains, it must be demonstrated that the product “can be expected to produce the same clinical result in any given patient and that the risk associated with alternat-ing or switching between the two products is not greater than that involved in continuing to use the reference product.” FDA will develop the regulatory standards for use of inter-changeable biosimilars and will also develop standards to ensure that products

not deemed interchange-able “are not inadvertently substituted for a reference product without the pre-scriber’s consent.”

In an article published in The New England Journal of Medicine, FDA scientists from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) detail the challenges in developing a biosimilar approval pathway and provide information about the scientific ap-proaches being considered.

The authors note some of the challenges in bal-ancing science and the regulatory framework, and point to the direction FDA is taking as it develops an approval pathway. FDA believes that a “one size fits all” approach is unlikely.

FDA explains that currently a “totality of evidence” approach along with FDA’s experience in identifying fingerprint-like patterns “will be essential in designing a U.S. biosimi-lars policy that encourages development of biosimilars, emphasizing the use of innovative technologies.” Totality of evidence involves FDA scientists integrating “various types of informa-tion to provide an overall assessment that a biologic is biosimilar to an approved reference product.” FDA has begun to identify the challenges with the totality of evidence approach and considered how to work

with manufacturers in the pre-approval process. FDA will use a familiar risk-based approach in evaluating biosimilars, and the process will include product-specific safety monitoring.

In developing the forth-coming draft guidance for biosimilar applicants, FDA continued to assess informa-tion received at its Novem-ber 2010 public meeting, and on July 29, 2011, FDA held a public stakeholder meeting to discuss recommendations for the developing biosimi-lars user fee program. At that time FDA provided an update on the agency’s implementation of the BPCI Act and described the roles of the three committees that have been established to ensure consistency in FDA’s regulatory approach and guidance to applicants regarding development pro-grams for proposed biosimi-lar biological products. The committees include:

• the CDER Biosimilar Review Committee,

• the CBER Biosimilar Review Committee, and

• the CDER/CBER Bio-similar Implementation Committee (BIC). FDA stated that “the

CDER/CBER BIC is the forum to discuss policy issues, while the review committees focus on product-specific and scientific issues related to applicants’ requests for ad-vice concerning proposed biosimilar development programs.”

nabp newsletter

208

Legal Briefs

School Gets In Your FacebookBy Dale J. Atkinson, JD

In recent times, the regulatory community has questioned more and

more the role (or obligation) educational programs have in communicating ultimate criteria for licensure to its applicants and graduates. That is, are educational programs required to undertake an initial assessment of applicants to the program regarding, for example, one’s criminal history or moral character as such a background may be an impediment to eventual licensure, in spite of graduation and successful completion of the licensure examination? What obligations do educational programs owe to admitted applicants who will expend time and monies to the school only to potentially be deemed ineligible for licensure based upon past transgressions occurring prior to enrollment in the program?

This question is fur-ther emphasized in certain educational programs where placement of enrolled stu-dents in medical settings is a requirement to graduation and such medical settings mandate criminal back-ground checks and reserve the right to deny placement. Under this scenario, a cur-rently enrolled student who has completed a significant portion of the curriculum may be precluded from or limited in opportunities for placement in an intern-ship/externship mandated for graduation. Finally, the proliferation of for-profit schools/programs has placed further scrutiny on these is-

sues as an argument can be made that schools/programs focus on enrollment num-bers, rather than quality of applicants.

One legislative attempt to address these issues comes from the state of Texas, which mandates that every individual who applies for a license with the Texas Department of Licensing and Regulation (the Depart-ment) and other boards that issue licenses is subject to a criminal background check to determine his or her suitability for the license. In 2009, the state enacted new provisions to allow a person to find out before applying for licensure (or for that

matter, before applying for an educational program) whether he or she would likely be denied a license due to his or her criminal his-tory, as determined by the Department or board at that time. The Department or board reviews the request-ing individual’s criminal convictions, deferred adjudications, and any other aspect of his or her criminal history that may have bear-ing on a license application. Within 90 days of receiving a complete request, it will issue a criminal history evaluation letter stating that the Department would or would not recommend granting a license to the requestor, based on all of the information available to the Department at that time. The Department’s view of the requestor’s criminal background may be differ-ent at the time of an actual license application, due to a change in the requestor’s circumstances, discovery of additional information not previously known to the Department or board, or a change in the Department or board’s policies relating to applicants’ criminal back-grounds.

Under any circum-stances, a ruling at the time of licensure application to a regulatory board is also dependent upon successful completion of the educa-tional program, licensure examinations, and other criteria contained in the practice act. Nonethe-

november-december 2011

209

Legal Briefs

Attorney Dale J. Atkinson is a partner in the law firm of Atkinson & Atkinson, outside counsel for NABP.

less, licensing boards will ultimately be asked to assess and determine licensure eligibility of applicants who may have a suspect past. Indeed, activities question-ing an applicant’s moral character may occur in the educational program. Con-sider the following.

Students in mortuary arts programs leading to licensure as funeral direc-tors and embalmers take significant laboratory courses, which involve the physical handling of human materials and cadavers, including dissection. Cadav-ers are acquired through an anatomy-bequest program of the university whereby the body of a deceased per-son is provided to the school and referred to as a “Donor.” All mortuary arts students participate in orientation programs that address appropriate conduct with respect to Donors and, in addition, sign acknowledge-ments agreeing to abide by the school’s code of conduct.

During November and December 2009, a student of the school posted on her Facebook page several postings that referred to her cadaver as “Bernie” (derived by the student from the movie Weekend at Bernie’s) and also referenced the use of a scalpel and a trocar in an embalming exercise related to aspirating a cadaver. In addition, the student posted references to wanting to “stab a certain someone in the throat with

a trocar” and that she will spend time “updating my ‘Death List #5’ and making friends with the crematory guy.” Finally, her Facebook postings stated that Bernie would no longer be with her, that she would miss him, and that she maintained a “lock of [Bernie’s] hair in her pocket.” According to her Facebook settings, these postings were allowed to be viewed by “friends” and “friends of friends” of the student, which amounted to hundreds of people.

A fellow student who also worked for the anato-my-bequest program of the university reported concerns over the student’s postings to the school administra-tion personnel. The direc-tor of the mortuary arts program met with depart-ment faculty and the police regarding these postings. No criminal charges were filed, but the student, after a hearing conducted by the Campus Committee on Stu-dent Behavior (CCSB), was found responsible for violat-ing several sections of the code of conduct. As a result, she was sanctioned by being given a failing grade in the lab class, required to enroll in an ethics class, write a letter to faculty regarding respect to the program and cadavers, and complete a psychiatric evaluation. Her internal appeals were denied as the provost affirmed the CCSB findings and held that her actions were “disre-spectful, unprofessional,

and reasonably interpreted as threatening.” The student appealed the matter to the state of Minnesota Court of Appeals.

On appeal, the student argued, among other things, that her Facebook posts were protected literary expressions and subject to protections of free speech under the First Amendment of the United States Constitution. The court noted that although student speech is afforded broad constitutional protec-tions and that “state col-leges and universities are not enclaves immune from the sweep of the First Amend-ment,” that schools may limit or discipline student expression if school officials “reasonably conclude that it will ‘materially and substan-tially disrupt the work and discipline of the school.’” In determining such to be the standard, the court rejected the student’s argument that an “actual threat” is the threshold from exempt-ing expression from First Amendment protections. In making this argument, the student emphasized that her postings were not an actual threat but were in response to a recent break-up with a boyfriend and, when read in context, obviously constitute “literary expression intended to be satirical, vent emotion, and incorporate popular culture references.”

Thus, the court narrowed the issue to whether the student postings materially

(continued on page 210)

nabp newsletter

210

Executive Officer Forum

Legal Briefs(continued from page 209)

and substantially disrupted the work and discipline of the school. In finding for the school, the court held that these posts were violent, threatening, and solicited attention from those in the anatomy-bequest program, potentially adverse to the acquisition of Donors. Fur-ther, the testimony indicated that multiple students and professors felt threatened as potential targets of her “Death List” and that such clearly disrupted the work of the school.

The court also rejected the arguments of the student that the activities occurred off campus and were thus not subject to the authority or jurisdiction of the school. Citing the code of conduct, the court found that off campus activity can form the basis of student discipline as such is ex-plicitly stated within the code. As far as specific rules

within the code alleged to have been violated, the court upheld some of the findings of violations, while overturning others. The court upheld the postings to constitute threatening conduct, that Facebook posts constitute “blog-ging” as referenced in the code, and that her actions violated the disclosure form signed by mortuary arts students as related to Donors. The court found in favor of the student as to the fact that her postings did not, as defined in the code, constitute “physical handling” of a cadaver, did not implicate “funeral ser-vice,” and did not substan-tiate that the student “failed to treat a decedent with proper care and dignity during transport.”

However, based upon its conclusions, the court affirmed the findings and sanctions of the school, noting that appellate courts generally defer to the universities in student

discipline matters. The court upheld the sanctions imposed by the school and affirmed the holding of the CCSB and provost.

Assuming such infor-mation is available for the licensing boards, the behavior of students within an educational setting may provide a basis for a more in-depth moral character assessment when and if such student even-tually seeks licensure by the applicable state board. Readers are reminded of the Albany College of Pharmacy (ACP) case reported on in the article, “Compounded Diploma,” referencing Papelino v Albany College of Pharmacy, Union University, 2009 WL 2957789 (US DC NY 2009) and published in the November-December 2009 NABP Newsletter. In that article the concluding paragraph stated:

Thus, the District Court ruled in favor of ACP in granting its request for

summary judgment. The educational standards under which applicants for licensure as pharma-cists must meet neces-sitates, at times, the veri-fication or certification of the academic achieve-ments of the student-applicant for licensure. Educational programs have an obligation to not only their students, but the licensing boards that rely upon the gradua-tion as one criterion in the licensure process. The above represents an interesting approach to refusing to certify a student who received a diploma.Stay tuned as there

has been activity on the Papelino case reversing in part the lower court ruling and such will be the topic of a future NABP Newslet-ter Legal Briefs article.

Tatro v University of Minnesota, Case Number A10-1440 (App. Ct. MN 2011)

Executive Officer Forum(continued from page 206)

and services that are avail-able to the attendees as well as a call for nominees for the awards presented at the NABP Annual Meeting. He thanked attendees for their participation and encour-aged the executive officers in attendance to support the next interactive forum, which is geared for compli-ance officers, inspectors, and investigators.

The Interactive Compli-ance Officer Forum will be held December 1-2, 2011, rather than waiting until 2012. Attendee feedback prompted this change, as members and executive of-ficers expressed their desire to meet more frequently than every three years, as was initially planned. The time period was condensed to allow members and compli-ance staff to meet every other year, and executive officers to meet annually.

The Interactive Compli-ance Officer Forum will be modeled after the previous forums with feature panel discussions and networking over a two-day period. In ad-dition, the annual NABP sur-veyor training will be held at the same time and surveyors will participate in some of the Interactive Forum sessions. By combining the surveyor training session with the Forum, NABP surveyors will have the chance to learn directly from board of phar-

macy compliance officers, inspectors, and investigators what their typical duties and challenges entail. NABP will again cover all expenses for one member from each board in order to facilitate participation by as many boards as possible and allow for increased opportunity for networking as compli-ance officers, inspectors, and investigators use the Forum to share ideas and develop potential solutions to meet common challenges.

november-december 2011

211

Association News

NABP PMP InterConnect Steering Committee Finalizes Governance Structure and Policies

The NABP PMP In-terConnectSM Steering Committee met August 30-31, 2011, to finalize the governance structure of the committee and develop policies and procedures, as well as to review implemen-tation progress and discuss administrative matters.

The Steering Committee governs the NABP Inter-Connect and is composed exclusively of representa-tives of the prescription monitoring programs (PMPs) that are participat-ing in the NABP InterCon-nect system. The Steering Committee serves as the governing and advisory body as it relates to the ad-ministration and function of the NABP InterConnect. No outside organization, public or private, has access to the NABP InterConnect, a vote about, influence over, or the ability to direct the administration and func-tion of the NABP Inter-Connect. Outside parties and subject matter experts may, however, be invited by the Steering Committee to provide information for the committee’s consideration from time to time.

“The composition of the steering committee – including representatives of all states that have signed the memorandum of understanding [MOU] to participate – has been critical to the success of the NABP InterConnect by helping to ensure that the system meets each

state PMP’s needs,” says Danna Droz, RPh, JD, PMP administrator, Ohio Automated Rx Report-ing System. Droz states further that “bringing in ideas and information from states that are planning to participate or consider-ing participation has also benefitted the development of the NABP InterConnect system. To achieve the goal of interoperability among all state PMP systems, including all current and potential participants is the best course of action.”

GovernanceCurrently, the Steering

Committee is composed of representatives of participat-ing PMPs in the following states: Arizona, Connecticut, Indiana, Kansas, Michigan, Mississippi, New Mexico, North Dakota, Ohio, South Carolina, Virginia, and West Virginia. Additional mem-bers will join as they agree to participate and execute the MOU with NABP.

At the August meeting, committee members unani-mously adopted operating principals that will govern the activities and interactions of the committee, including the following:

• A chairperson of the com-mittee will be appointed annually by the NABP president.

• Voting (active) members of the committee will be composed of those states that have executed an MOU with NABP for

participation in NABP InterConnect.

• The committee, through the chairperson, may invite other states to participate in the Steer-ing Committee as guests. The committee, through the chairperson, may invite other guests to participate, attend, or observe the Steering Committee meetings. Such individuals may include the technology solution provider for NABP InterConnect; PMP software vendors; relevant federal or state agencies or national as-sociations dedicated to patient safety, safe drug use, and deterring diversion of controlled substances; or any other person as determined by the discretion of the chairperson.

More information about the NABP InterConnect Steering Committee and these operating principles is available in the Pro-grams section of the NABP Web site at www .nabp.net/programs.

Funding and Expenditures

NABP is paying for all costs associated with the development and imple-mentation of the NABP InterConnect, as well as five years of annual participa-tion fees for each participat-ing PMP using, exclusively, its own revenues derived from program resources and its reserves. NABP has the financial resources to make this commitment

NABP InterConnect Implementation Moves Forward

Three states – Ohio, Indiana, and Virginia – have gone live with the NABP InterConnect, with Ohio and Indiana allowing authorized PMP users statewide to request data from among the three PMPs, and Virginia allowing select users to request data.

Nine additional states have executed an MOU with NABP to participate in the NABP InterConnect: Arizona, Connecticut, Kansas, Michigan, Mississippi, New Mexico, North Dakota, South Carolina, and West Virginia.

The following PMPs intend to sign on to use the NABP InterConnect and have MOUs under review: Delaware, Louisiana, Montana, Nevada, North Caro-lina, Rhode Island, and South Dakota.

It is anticipated that approximately 30 states will be sharing data using the NABP InterConnect in 2012.

(continued on page 224)

nabp newsletter

212

Association News

Counterfeit Drugs Distributed Via Internet Endanger Unsuspecting Patients; NABP Reports on Progress in Fighting Rogue Sites

Counterfeiters and rogue sellers take advantage of patient confidence in trusted brands to sell pills that may contain too much or too little, if any, of the approved drug’s active ingredient, an entirely different active ingredient, or contaminants ranging from talcum powder to printer ink. Prescription medications indicated for the treatment of erectile dysfunction (ED) are among the most commonly counterfeited drugs, and they are frequently bought and sold over the Internet. Embarrassed to discuss ED symptoms with their doctors, patients instead place their health in the hands of unknown drug sellers, many of whom turn a hefty profit by selling dangerous, substandard, and counter-feit drugs without regard for patient safety.

While a precise number of Web sites selling counterfeit drugs is difficult to determine, their prevalence and ill effects have garnered the attention of medical professionals, health regulators, and enforcement agencies worldwide. The prev-alence of counterfeit ED drugs on the Internet, the ongoing efforts to educate patients, and the enforcement actions taken to shut down rogue sites are discussed in the Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators: October 2011.

As indicated in the report, NABP has identified 3,703 Web sites selling drugs that have not been tested or ap-proved by the United States

Food and Drug Administra-tion (FDA) and are illegal to sell in the US, and most of these sites offer unapproved ED remedies. In addition to Web sites selling foreign and unapproved drugs, approxi-mately 85% of the sites NABP lists as Not Recommended sell prescription medication without requiring a valid prescription, exposing patients to additional health risks. The NABP report also cites recently published academic studies that have investigated the prevalence of counterfeit drugs distributed to patients in the US and abroad via fraudulent Web sites. When sold at market price, the report notes, counterfeit ED drugs re-portedly can generate 2,000% profit margins – approximate-ly 10 times the profitability of heroin. Additionally, penalties for the illegal sale of prescrip-tion drugs are generally less severe than for illicit drugs.

Counterfeit pills have been seized at the border by US Customs and Border Protection; and, in other countries – including the United Kingdom, Singapore, and Hong Kong – counterfeit drugs have made their way to consumers, often with devas-tating health consequences.

Responding to the need for global action, FDA, along with regulatory agencies from 81 countries, participated in the International Internet Week of Action, September 20-27, 2011. The project, dubbed Operation Pangea IV, was a cooperative effort to curb online sales and distri-

bution of counterfeit and ille-gal medical products. During the project, FDA targeted 997 Web sites that were illegally selling unapproved and/or misbranded drug products, including ED remedies, to US consumers. FDA reports that of 717 sites identified and sent warning letters, 578 “have been suspended or no longer offer pharmaceuticals for sale.” INTERPOL reports that, as a result of the efforts of all of the project’s interna-tional partners, nearly 13,500 Web sites engaged in illegal activity were shut down.

NABP is taking steps to expose the dangers of counterfeit drugs and rogue Internet drug outlets, and to assist regulatory and enforce-ment agents in eliminating these unlawful practices. NABP is partnering with Pfizer Inc to draw attention to the risks associated with counterfeit drugs and to help patients learn to identify safe Internet pharmacies. Pfizer and NABP’s educational initiative includes a YouTube video series, available at www.YouTube.com/spotfakemeds, that features experts from Pfizer, NABP, Microsoft, and the cyber-security company McAfee. NABP provides the AWARxE™ consumer protec-tion program as a resource not only for consumers, but also to help the boards of pharmacy, their licensees, and other stakeholders educate patients on medication safety. The Web site, www.AWARErx .org, provides information about rogue Internet drug

outlets, prescription drug counterfeiting, proper medi-cation disposal, and other medication safety issues.

As indicated in the Oc-tober 2011 progress report, NABP has assessed 8,445 Internet drug outlets selling prescription medications and has found 8,122 (96.17%) of them to be out of compli-ance with state and federal pharmacy laws and practice standards. These sites are listed as Not Recommended in the “Buying Medicine On-line” section of the Programs page on the NABP Web site. Of these Not Recommended sites:

• 6,897 do not require a valid prescription

• 5,162 issue prescriptions per online consultation or questionnaire only

• 3,703 offer foreign or non-FDA-approved drugs

• 2,106 are located outside of the US and selling drugs illegally to patients in the USOf the total 8,445 sites

reviewed, 260 (3.08%) appear to be potentially legitimate in that they meet program criteria, based on information obtained by looking at the sites. Sixty-three (0.75%) sites have been accredited through NABP’s VIPPS® (Verified Internet Pharmacy Practice SitesCM) or Vet-VIPPS® pro-grams, or approved through the NABP e-Advertiser ApprovalCM Program. The In-ternet Drug Outlet Identifica-tion Program progress report is available on the NABP Web site at www.nabp.net/news.

november-december 2011

213

Association News

Boards Report 846 Disciplinary Actions in Third QuarterReporting trends contin-

ue to reflect efforts by boards of pharmacy to report disci-plinary actions to the NABP Clearinghouse. During third quarter 2011, a total of 846

Figure B: Basis for Disciplinary Actions Reported Third Quarter 2011*The miscellaneous category includes default on health education loan or scholarship obligations; filing false reports or falsifying records; immediate threat to health or safety; improper or inadequate supervision or delegation; malpractice; misleading, false, or deceptive advertising or marketing; negligence; nolo contendere plea; other – not classified; practicing beyond the scope of practice; substandard or inadequate care; and unable to practice safely.

actions were reported to the NABP Clearinghouse, with 572, or 67%, of these taken against pharmacists and the remaining 274, or 33%, taken against pharmacy

technicians. Administrative or publicly available fine/monetary penalty accounted for the most actions reported with 164, or 19.4%, of the total 846 actions. Probation

of license was the second most reported action during the third quarter with 143, or 16.9%, of the actions reported. The third most common action reported was voluntary surrender of license, with 123, or 14.5%, of the total actions. (See Figure A.)

Data indicates that of all the actions taken during the third quarter, 20.3% were taken due to violation of federal or state statutes, regulations, or rules. Con-sisting of several smaller categories, the miscel-laneous category held the second highest percentage overall with 17.3%. Another 9.8% of the actions report-ed during the third quarter were taken due to alcohol and/or other substance abuse. (See Figure B.)

Regularly updated, the NABP Clearinghouse is available to serve as a comprehensive resource for the boards of pharmacy. It houses a tremendous amount of disciplinary data provided by the boards and tracks everything from the actions taken to the basis for the actions. NABP also offers its services as a reporting agent for the Healthcare Integrity and Protection Data Bank and information is available at www .nabp.net/programs/member-services/nabp-clearinghouse.

The Association ap-plauds the boards of phar-macy in their continued efforts to protect the public health through disciplinary action reporting.

19.4%

16.9%

14.5%11.3%

10.2%

9.9%

8.3%

5.8%3.7% Administrative or Publicly Available

Fine/Monetary Penalty (19.4%)

Probation of License (16.9%)

Voluntary Surrender of License (14.5%)

Revocation of License (11.3%)

Micellaneous* (10.2%)

Reprimand or Censure (9.9%)

Suspension of License (8.3%)

License Restored or Reinstated, Complete and Conditional (5.8%)

Summary or Emergency Suspension of License (3.7%)

Figure A: Disciplinary Actions Reported Third Quarter 2011*The miscellaneous category includes denial of license renewal, extension of previous action, license restoration or reinstatement denied, limitation or restriction on license, other licensure action – not classified, and reduction of previous action.

20.3%

17.3%

9.8%8.4%

7.6%

4.5%

3.7%

3.7%3.1%

2.7% 2.4% 0.7%

9%

7%

Violation of Federal or State Statutes, Regulations, or Rules (20.3%)

Miscellaneous* (17.3%)

Alcohol and/or Other Substance Abuse (9.8%)

Diversion of Controlled Substance (9%)

Narcotics Violations (8.4%)

Error in Prescribing, Dispensing, or Administering Medication (7.6%)

Failure to Comply with Continuing Education or Competency Requirements (7%)

Criminal Conviction (4.5%)

Fraud (3.7%)

License Revocation, Suspension, or Other Disciplinary Action Taken by a Federal, State, or Local Licensing Authority (3.7%)

Violation of or Failure to Comply With Licensing Board Order (3.1%)

Practicing Without a Valid License (2.7%)

Unauthorized Dispensing or Prescribing of Medication (2.4%)

Allowing or Aiding Unlicensed Practice (0.7%)

nabp newsletter

214

Association News

FPGEE Competency Statements and Blueprint UpdatedThe Foreign Pharmacy

Graduate Equivalency Examination® (FPGEE®) competency statements and blueprint have been updated and will be implemented begin-ning with the April 2012 administration. The four major content areas of the FPGEE will remain the same, however, upon evaluation the subtop-ics were modified. In addition, the percent-age breakdown for each content area has been adjusted as follows: Basic Biomedical Sciences (16%), Pharmaceutical Sciences (30%), Social/Behavioral/Administra-tive Sciences (22%), and Clinical Sciences (32%).

The timing of the update is in accordance with recommended testing industry stan-dards, which typically require the review and, if necessary, update of examination blueprints at least every five years. Last updated in 2007, the FPGEE competency statements and blueprint are reviewed regularly to ensure that the exami-nation content remains consistent with the entry-level doctor of pharmacy programs in the United States.

Specific revisions were made as a result of responses received from a 2010 College of Phar-macy Curricula Survey. One hundred and twelve schools and colleges of pharmacy were invited to

participate in the survey, which was developed using input from NABP examination review com-mittee members. With a return rate of nearly 60%, the survey received responses from a total of 66 pharmacy schools from across the nation. In addition, all eight NABP/American Associa-tion of Colleges of Phar-macy districts were rep-resented. These districts were created to represent the boards and schools of pharmacy through-out the US, District of Columbia, Guam, Puerto Rico, and Virgin Islands. The survey respondents also represented the diversity of the pharmacy schools throughout the US with respect to size, geographic location, whether the schools were public or private institu-tions, etc.

As part of the up-date process, NABP also conducted a standard-setting meeting consist-ing of educators who represented 24 schools of pharmacy. The purpose of this standard setting was to recommend an appro-priate passing standard for the FPGEE. The com-mittee’s recommendation was first presented to the FPGEE Review Com-mittee and then to the Advisory Committee on Examinations who has recommended a passing standard to the NABP Executive Committee for final approval.

The updated FPGEE competency statements and blueprint are avail-able on the NABP Web site at www.nabp.net/programs/examination/fpgee.

Scores, Upcoming Administration

Scores for the Septem-ber 27, 2011 FPGEE were released in October and made available for candi-dates to view on the NABP Web site.

The next FPGEE will be administered on April 19, 2012. NABP will open FPGEE registration in Jan-uary 2012, and candidates will have until April 6, to register. Candidates must register for the examina-tion on the NABP Web site before they can choose a location to take the FPGEE. Within one week after registering, candidates will receive an Authorization to Test, and they may then schedule their test loca-tion with the NABP test vendor, Pearson VUE. The deadline to schedule a test location with Pearson VUE is April 10.

FPGECThe FPGEE is one com-

ponent of the Foreign Phar-macy Graduate Examination Committee™ (FPGEC®) Certification Program. NABP developed the FPGEC as a means of documenting the educational equivalency of a candidate’s foreign phar-macy education and foreign license and/or registration, which assists state boards of pharmacy in qualifying

candidates for licensure in the US.

To qualify for the FPGEC Certification Program, candidates are required to submit proper documenta-tion from educational or licensure institutions that represent their educational backgrounds and licensure and/or registration to prac-tice pharmacy. In addition, candidates must pass the TOEFL iBT® (Test of Eng-lish as a Foreign Language Internet-based Test), which is administered by Educa-tional Testing Service. The FPGEC Certificate allows foreign graduates to par-tially fulfill eligibility re-quirements for licensure in the 50 United States, Guam, and the District of Colum-bia where the certification is recognized.

To prepare for the FPGEE, NABP recom-mends that candidates take the Pre-FPGEE®, the only FPGEE practice examina-tion written and developed by NABP. This practice examination is designed to help familiarize applicants with the FPGEE by exhibit-ing the types of questions provided on the actual examination.

Additional informa-tion on the FPGEE as well as the Pre-FPGEE is avail-able at www.nabp.net/ programs.

november-december 2011

215

Association News

ACPE-Accredited Providers Participate in CPE Monitor Pilot, Begin to Require NABP e-Profile ID for CPE Credit Submission

Since the initial launch of the CPE Monitor™ service in March, more than 85,100 pharmacists and 31,400 pharmacy technicians have set up their NABP e-Profiles as they prepare for the shift to electronic tracking of all Accreditation Council for Pharmacy Education (ACPE)-accredited continu-ing pharmacy education (CPE) units. As a secure, central system, CPE Monitor will maintain and track all ACPE-accredited CPE units.

ACPE is now working with a select group of CPE providers and NABP to pilot the transmission of pharmacists’ and pharmacy technicians’ CPE credit. In early September, ACPE sent detailed technical specifica-tion documents to a group of 42 ACPE-accredited providers who volunteered to participate in the pilot. The document described how to use the CPE Moni-tor system, how to exchange information with ACPE, what format the informa-tion should be in, and how to receive confirmation that CPE activity data was successfully processed. Recently, the providers par-ticipating in the pilot began uploading and transmitting pharmacists’ and techni-cians’ CPE credit electroni-cally to ACPE, which then sends the verified data to NABP. To accomplish this, these providers also began requiring that pharmacists and technicians provide their NABP e-Profile ID

and date of birth (MMDD) before submitting the CPE activity for credit.

Though this initial data transmission is currently only for testing purposes, ACPE and NABP intend to store the validated CPE data in CPE Monitor for future use by licensees and the state boards of pharmacy. Data collected via this system is not used or distributed for commercial purposes. The provider pilot is anticipated to last through December 2011.

Upon successful com-pletion of the pilot and verification that all CPE information is properly and accurately uploaded, recorded, and tracked, all ACPE-accredited provid-ers will begin updating their systems for electronic transmission of CPE data. Those providers who already participated in the pilot will continue to up-load and transmit licensees’ CPE data directly to ACPE. It is anticipated that in early

2012 additional providers will begin transitioning to the CPE Monitor service, and that the majority of the ACPE-accredited providers will have CPE Monitor in-tegrated into their systems by July 2012. All providers will be required to trans-mit their CPE data in this manner by December 31, 2012, in order to continue to issue ACPE-accredited CPE units.

NABP strongly encour-ages all pharmacists and pharmacy technicians to set up their NABP e-Profiles now so that they are pre-pared once providers begin requiring the e-Profile ID. This will assist in elimi-nating any delays in the processing and tracking of CPE data.

CPE Monitor utilizes a streamlined process, thereby eliminating the need to file and maintain hard copy statements of credit for CPE activities taken from ACPE-accred-ited providers. Instead,

online access to a registry of completed credits will allow pharmacists and pharmacy technicians to more easily monitor their compliance with the CPE requirements of the state(s) where they hold a license or registration. Licensees of participating boards will no longer have to mail a hard-copy proof of CPE statements of credit to those boards. Licensees will also be able to print a certificate containing the data transmitted to NABP by ACPE for licens-ing jurisdictions who may require such paper docu-mentation to be submitted.

Licensees may obtain additional information and set up their e-Profiles at www.MyCPEmonitor .net.

CPE Monitor Data Exchange ProcessThe above chart demonstrates the basic flow of a pharmacist’s or technician’s CPE data through the CPE Monitor service.

Pharmacist or

Technician

ACPE-Accredited

CPE ProviderACPE NABP

Participating State Boards of Pharmacy

Pharmacist or

Technician

nabp newsletter

216

Executive Officer Forum

Executive Officer Forum Panelists Lead Discussions on Common Issues Faced by the State Boards of Pharmacy

Split between two days, timely and relevant sessions afforded attendees of the NABP Interactive Executive Officer Forum the opportunity to discuss common issues state boards of pharmacy face. Presenters from the boards kicked off each discussion by sharing noteworthy experiences relating to each of the topics. More information on the Forum can be found in the cover story of this Newsletter.

Exploring the PracticeOn September 21, 2011, speakers delved into various topics that have the potential to affect pharmacy practice during the first session of the Executive Officer Forum, “Is This the Practice of Pharmacy?” Pictured from left to right: Ron Guse, B.SC. Pharm, registrar, Manitoba Pharmaceutical Association (Internet Pharmacies); Frank Gammill, executive director, Mississippi Board of Pharmacy (Regulation of PBMs); Mark Whitten, executive director, Florida Board of Pharmacy (Pill Mills); session moderator Karen M. Ryle, MS, RPh, NABP treasurer; and Moira Gibbons, PharmD, JD, legal affairs senior manager, NABP (FTC v NC Board of Dentistry).

NABP President Broussard Welcomes Executive Officers After a brief tour of NABP Headquarters, attendees of the Interactive Executive Officer Forum convened in the NABP Training Room where they were welcomed by NABP President Malcolm J. Broussard, RPh. Following Broussard’s remarks, attendees enjoyed a catered networking dinner in the NABP café.

november-december 2011

217

Executive Officer Forum

Meeting Common ChallengesState board of pharmacy representatives expressed their viewpoints on specific state issues during the session “Shared State Topics.” Pictured from left to right: Gay Dodson, RPh, executive director/secretary, Texas State Board of Pharmacy (Pharmacy Robberies); Virginia “Giny” Herold, MS, executive officer, California State Board of Pharmacy (Dwindling Board of Pharmacy Resources: Challenges for Chief Administrative Officers); Caroline Juran, RPh, executive director, Virginia Board of Pharmacy (Prescriber Dispensing); and session moderator Hal Wand, MBA, RPh, member, NABP Executive Committee.

Pharmacy Technology: A Closer LookThe second day began with the session “Technology: Progress or Problems,” during which speakers shared how technology is affecting the practice of pharmacy. Pictured from left to right: Joshua Bolin, BA, government affairs director, NABP (NABP PMP InterConnect Uses); session moderator Edward G. McGinley, RPh, MBA, member, NABP Executive Committee; Lawrence H. Mokhiber, MS, RPh, executive secretary, New York State Board of Pharmacy (Automated Dispensing Systems); and Howard C. Anderson, Jr, RPh, executive director, North Dakota State Board of Pharmacy (Virtual Wholesale Distributors).

How Many Facebook Friends Do You Have?The session “Social Media Trends: Life in 140 Characters or Less,” explored social media as it applies to the boards of pharmacy. Pictured from left to right: session moderator Joseph L. “Joe” Adams, RPh, member, NABP Executive Committee; Phil Wickizer, JD, director, Indiana Board of Pharmacy; and Lloyd K. Jessen, RPh, JD, executive director, Iowa Board of Pharmacy, and member, NABP Executive Committee.

nabp newsletter

218

AWARxE

GreyGrey: Black Process 70% Black: Process 100K

TM

GET INFORMED | www.AwARERx.oRg

AWARxE Across America – Learn How Your Board Can Get Involved Help Patients Practice Safe Medication Use and

Protect their Families from Misuse

Across the nation, AWARxETM outreach efforts have expanded and you and your board may help to am-plify the AWARxE message in your state’s communi-ties. AWARxE’s national ad campaign, public service announcements (PSAs), and new print materials are currently supporting efforts across the country to raise awareness about prescription drug abuse, medication safety, the dangers of counterfeits, and proper drug disposal to prevent misuse.

Boards of pharmacy can become involved in the AWARxE Across America effort by sharing resources with licensees, registrants, and consumers in the follow-ing ways:

•Distribute AWARxE bookmarks at public board meet-ings, through board mailings, or in association with other board activities (see images at bottom right).

• Post the AWARxE logo linked to WWW.AWARERx.ORg on your board’s Web site, in addition to posting the NABP logo and link.

• Share relevant news with AWARxE, such as details on drug disposal programs in your state and other board programs aimed to fight prescription drug abuse, for inclusion on your state’s AWARERx.ORG Get Local page.The Oregon State Board of Pharmacy and a student

group at the University of Tampa plan to use bookmarks in support of outreach and educational efforts in their states. NABP has also provided bookmarks to commu-nity events, including a local charity race, potentially reaching hundreds of consumers concerned about health issues.

To order bookmarks at no charge to the board, or to obtain the AWARxE logo for a Web site, send an e-mail to AWARERx@NABP.NET.

Further, the October and November editions of the AARP Bulletin contained AWARxE advertisements highlighting the “Does a Drug Dealer Lurk in Your Medicine Cabinet?” theme. The ad campaign encourag-es consumers to visit the AWARxE Web site where they can learn how to protect their families from prescription drug misuse and abuse with proper drug disposal, and from counterfeit drugs by using only VIPPS® (Verified Internet Pharmacy Practice SitesCM)-accredited pharma-cies when ordering medications online.

Campaign efforts will be enhanced with AWARxE PSAs being promoted beginning November 2011. The PSAs – promoting awareness about prescription drug abuse and the risks of counterfeit drugs sold online – are posted on the AWARxE YouTube channel (www.youtube .com/user/AWARxE) and may be coming to a TV sta-tion near you soon! The PSAs are being promoted in 16 geographical market areas, including TV stations in the following states and jurisdictions:Arizona Connecticut Florida IllinoisKentuckyLouisiana

Massachusetts Minnesota Nevada New YorkNorth DakotaOhio

OklahomaOregon Texas Washington DC

AWARxE also continues to reach out to seniors and their caregivers through exhibits at expos. NABP staff shared AWARxE resources and information with several thousand seniors in August 2011 at the Senior Lifestyle Expo, Oak Brook Terrace, IL, and in September 2011 at the Active Senior Expo, St Charles, IL. AWARxE will also have a booth at the Managed Healthcare Provider’s Association Symposium held in Oak Brook Terrace, IL, on November 18, 2011.

Choose from one of three AWARxE bookmarks: (1) aimed to consumers; (2) aimed to pharmacy customers; or (3) aimed to students/young adults. Facts and key topics on each of the three bookmarks are aimed for the particular audience. Pictured here: pharmacy customer bookmark. (Please note, these are available as three-color bookmarks with text in black, white, and red.)

Front Back

november-december 2011

219

Association News

NABP Moving to New Linear Test Form Assembly Process to Enhance Association’s Examination Programs

NABP is in the process of evaluating and revis-ing its test form assembly processes, moving from computer adaptive forms to linear, in-house form assembly. This shift to linear examination form assembly will assist NABP in maximizing the usage of existing test item pools while controlling item exposure. Additionally, this type of form assembly will help to streamline publica-tion processes, standardize examination development across NABP programs, and enhance examination security.

The first of the examina-tions to undergo this new assembly process is the North American Pharmacist Licensure Examination® (NAPLEx®). Utilizing cut-ting edge technology and adhering to testing industry standards, NABP is examin-ing all aspects of the NAPLEx to ensure that the new pro-cess produces highly reliable, pre-equated test forms.

The linear form as-sembly combines advanced technology utilizing the same strong theoretical foundation used for the current form assembly process. By following the

processes for linear form assembly, NABP is able to assemble equivalent test forms that maximize precision near the passing score while meeting all test specifications. In addition, to regulate the amount of item overlap and item ex-posure among the distrib-uted examinations, the new assembly process will create various sets of test forms, thus providing increased control and security. NABP will also have the capability to rotate sets of operational test forms, which will be beneficial during peri-ods of high test volume.

The overall examination development process will remain the same from item development and analysis, to scoring and reporting.

Upon successful comple-tion and implementation of the new NAPLEx form as-sembly project, NABP plans to begin similar processes for the Multistate Pharmacy Jurisprudence Examina-tion®, Foreign Pharmacy Graduate Equivalency Ex-amination® (FPGEE®), Pre-FPGEE®, Pre-NAPLEx®, Pharmacy Curriculum Outcomes Assessment®, and Pharmacist Assessment for Remediation Evaluation.

A full listing of NABP approved e-Advertisers is available on the NABP Web site at www.nabp.net.

Newly Approved e-AdvertisersThe following entities were accredited through the NABP e-Advertiser ApprovalCM Program:

Indian Trail Pharmacy, Incwww.indiantrailpharmacy.com

Navarro Discount Pharmacieswww.navarro.com

2012 PCOA Administration Approaching in January, New Computer-Based Format to be Available

The fifth annual Phar-macy Curriculum Outcomes Assessment® (PCOA®) ad-ministration is scheduled to be held January 23 to Febru-ary 4, 2012. Participating schools and colleges of phar-macy choose one date within this two-week time period to have the assessment admin-istered to their students.

Beginning with the 2012 PCOA, a computer-based format of the assessment will

be available. Each school has the option to administer ei-ther the computer-based for-mat or the paper-and-pencil format offered in past years. As of press time, 18 schools have signed up to participate in the administration, five of which plan to utilize the new computer-based format.

In addition to the new computer-based format, the PCOA competency statements and blueprint

for the 2012 administra-tion have been updated based upon the outcomes from the 2010 United States College of Pharmacy Cur-ricula Survey. The assess-ment will be composed of four content areas that are broken down into 28 sub-topics. These content areas are detailed on the NABP Web site at www.nabp.net/programs/assessment/pcoa/pcoa-content.

The PCOA is a com-prehensive assessment tool developed by NABP and key stakeholders in response to the need expressed by the US schools of pharmacy for an objective measure of student performance and growth in pharmacy curricula.

More information about the PCOA is available on the NABP Web site at www.nabp.net/programs/assessment/pcoa.

nabp newsletter

220

Association News

2012 Survey of Pharmacy Law Available in DecemberServing as a convenient refer-

ence source for individuals seeking an overview of the state laws and regulations that govern pharmacy practice, the updated 2012 Survey of Pharmacy Law will be available in mid-December.

The Survey, produced in a CD format, consists of four sections including a state-by-state overview of organizational law, licensing law, drug law, and census data. Newly added this year, a question in Section 17, Wholesale Distributor Licen-sure Requirements, asks which state agency has regulatory authority over

Sponsorship and Educational Grant Opportunities for NABP 108th Annual Meeting Now Available

Organizations have an opportunity to gain exposure through numerous sponsorship and educational grant op-portunities available at the NABP 108th Annual Meeting to be held May 19-22, 2012, at the Sheraton Philadelphia Downtown Hotel in Philadelphia, PA. Contributing organizations help NABP provide quality programs designed to assist board of pharmacy members, executive officers, and compliance

staff to meet their responsibilities for safeguarding the public health while creating visibility for the sponsoring organization.

Contributing organizations will be recognized by session or event, and will also be identified in meeting program materials, the NABP News-letter, on meeting signage, and on the NABP Web site at www.nabp.net. In addition, sponsoring organizations

contributing $5,000 or more to the meeting are entitled to two compli-mentary meeting registrations valued at $575 each. Contributions of $1,000 to $4,999 entitle the donors to one complimentary meeting registration.

For more details on sponsorship and grant opportunities, organiza-tions may contact NABP via e-mail at custserv@nabp.net or via phone at 847/391-4406.

Deadline Announced to Submit Proposed Amendments to the NABP Constitution and Bylaws

Proposed amend-ments to the NABP Constitution and Bylaws must be submitted be-tween Monday, February 20, 2012 and Thursday, April 5, 2012, to be con-sidered during the 108th Annual Meeting, to be held May 19-22, 2012, at the Sheraton Philadel-

phia Downtown Hotel in Philadelphia, PA. Amend-ments may be proposed by any active member board of pharmacy, the NABP Ex-ecutive Committee, or the Committee on Constitu-tion and Bylaws.

NABP requests that all amendments be submitted in writing to NABP Execu-

tive Director/Secretary Car-men A. Catizone at NABP Headquarters, 1600 Feehan-ville Dr, Mount Prospect, IL 60056 or via e-mail at exec-office@nabp.net. Submis-sion dates are established by the NABP Constitution and Bylaws, which specifies that proposed amendments may be accepted no earlier than

90 days and no later than 45 days before the First Business Session of the Annual Meeting.

For more information on the proposed amend-ments to the NABP Constitution and Bylaws, please contact the NABP Executive Office at exec-office@nabp.net.

medical device distributors. In addition, a newly added question in Section 22, Electronic Transmis-sion of Prescriptions: Computer-to-Computer, asks whether the state allows electronic prescribing of controlled substances.

Updates for the 2012 Survey were graciously provided by the state boards of pharmacy. In addi-tion to the boards’ support, NABP requested data from relevant health care associations for the Survey’s prescribing authority and dispens-ing authority laws in Sections 24 and 25, and laws pertaining to

the possession of non-controlled legend drugs and possession of controlled substances in Sections 26 and 27.

The Survey can be purchased on-line for $195 by visiting the Publica-tions section of the NABP Web site at www.nabp.net/publications.

All final-year pharmacy students receive the Survey free of charge through the generous grant of Pur-due Pharma L.P.

For more information on the Sur-vey, please contact Customer Service via phone at 847/391-4406 or via e-mail at custserv@nabp.net.

november-december 2011

221

State Board News

New DirectorJay Stewart, JD, is now the director of the Division of Professional Regulation at the Illinois Department of Financial and Professional Regulation. Stewart replac-es Don Seasock who served as acting director after Director Don Bluthardt left in fall 2010. Prior to this position, Stewart served as senior counsel for the Office of the Governor. He was also the executive director for the Better Gov-ernment Association for five years. Stewart earned his bachelor of arts degree in political science from State University of New York College at Plattsburgh and his doctor of jurispru-dence degree from DePaul University College of Law.

Board Member Appointments•Theodore Mala has

been appointed a public member of the Alaska Board of Pharmacy. Mala’s appointment will expire on March 1, 2013.

•Jeffrey Mesaros, PharmD, JD, MS, has been appointed a member of the Florida Board of Pharmacy. Mesaros’s appointment will expire on October 31, 2014.

•Gavin Meshad has been appointed a public mem-ber of the Florida Board of Pharmacy. Meshad’s ap-pointment will expire on October 31, 2013.

(continued on page 223)

Around the Association

KS Board Highlights Patient Safety Benefits of K-TRACS

The Kansas State Board of Pharmacy recently implemented its prescrip-tion monitoring program (PMP), called K-TRACS, which is designed to track the sale of controlled drugs and drugs of concern, including carisoprodol, tramadol, and Fiorcet®. The Board notes that al-though pharmacists are not required to use K-TRACS other than to report dis-pensing information, the benefits of obtaining query-ing access to obtain patient information are numerous. K-TRACS provides critical information for educating patients and treating them effectively. Kansas pre-scribers and pharmacists are able to use the patient information to supplement the patient’s evaluation, confirm the patient’s drug history, and document the patient’s adherence to medication therapy.

Further, prescribers and pharmacists are able to make well-informed decisions before prescribing or dispensing a controlled substance in cases where le-gitimate need may be ques-tionable. The Board stresses that using K-TRACS can also provide increased patient safety including the potential of identify-ing and treating patients who have a substance abuse problem. For more infor-mation about K-TRACS, visit the Board’s PMP Web site at www .hidinc.com/kansaspmp.

IA’s PMP Reduces Number of Patient Prescriptions from Multiple Prescribers or Pharmacies

The Iowa Board of Pharmacy’s PMP is proving to be a very successful health care tool for prescribers and pharmacists in Iowa. As of June 27, 2011, 2,597 prescrib-ers and 1,108 pharmacists have registered to use the program. The number of data queries by prescrib-ers grew by 164% between 2009 and 2010, from 16,806 queries in 2009 to 44,442 in 2010. The number of queries by pharmacists grew by 40% during the same time period, from 5,703 queries in 2009 to 7,988 in 2010.

The Iowa Board’s PMP is also showing significant increases in the use of con-trolled substances in Iowa. Since January 1, 2008, the number of patients receiv-ing Schedule II medications increased from 182,755 to 297,424 (a 63% increase). The number of total prescriptions for controlled substances grew by 9.4% between 2008 and 2010. The number of total doses of controlled substances dispensed grew by 8.6% during the same time period. This mirrors the 8.8% increase seen in the number of prescriptions issued for hydrocodone from 2008 to 2010. The program is successfully reducing the incidence of patients who utilize multiple pharmacies and multiple prescribers to obtain controlled substances. The number of patients who received controlled sub-stances from five or more

prescribers or pharmacies decreased by 39% between 2009 and 2010, from 3,293 incidents to 2,016. This downward trend is continu-ing in 2011. Additional in-formation on the state’s PMP is available in the August 2011 Iowa Board of Pharmacy Newsletter available for download at www.nabp.net/publications/assets/IA082011 .pdf.

WA Requires Electronic Tracking of Methamphetamine Precursor Products

As of October 15, 2011, Washington State law requires that sales of nonprescription products containing ephedrine, pseu-doephedrine, or phenylpro-panolamine be tracked and monitored using a real-time electronic system. Rules de-veloped by the Washington State Board of Pharmacy establish reporting require-ments for pharmacies, shop-keepers, and itinerant ven-dors that sell these restricted products; identify a process to request an exemption from electronic reporting; and provide record retention and security standards. The law also requires pharmacies to keep products containing methamphetamine precur-sors behind the counter or in a locked display case where it is not accessible to customers without as-sistance. The National Precursor Log Exchange for electronic tracking of meth-amphetamine precursors has been implemented in the state and will:

(continued on page 225)

nabp newsletter

222

Professional Affairs Update

(continued on page 224)

NCPDP White Paper Recommends Consistent Labeling for Prescription Acetaminophen

In the interest of pa-tient safety, the National Council for Prescription Drug Programs (NCPDP) has published a white paper providing recommendations to industry intended to fa-cilitate consistency in labels for both over-the-counter (OTC) and prescrip-tion products containing acetaminophen. The paper, NCPDP Recommendations for Improved Prescription Container Labels for Medi-cines Containing Acetamino-phen, calls for harmoniza-tion of standards across the industry so that patients can more easily recognize when prescription medica-tions contain the drug, use medications containing acetaminophen safely, and avoid overdose. Specifi-cally, to create uniformity with practices used in OTC acetaminophen labeling, the document recommends industry adopt the following guidelines for prescription container labels:1. Use complete spelling of

acetaminophen (do not abbreviate)

2. Standardize acetamino-phen concomitant use and liver damage warn-ing labels

3. Prioritize the warning label to print within the top three warnings for a medicine containing acetaminophenThe paper also includes

recommendations to promote patient “under-

standing of the prescription container label and calls on pharmacists and physicians to participate in patient education on the appropri-ate use of acetaminophen,” as noted in an NCPDP press release. The paper is available for download at www.ncpdp.org/pdf/NCPDPacetaminophenWPfinal02Aug2011.pdf.

DEA Guidance: Information Pharmacists May Provide on CS II Prescriptions

Recognizing that phar-macists are sometimes presented with prescriptions for Schedule II controlled substances (CS) that are missing information re-quired by law, Drug Enforce-ment Administration (DEA) has provided guidance for pharmacists regarding al-lowed changes or additions to such prescriptions. First, DEA reminds pharmacists of the corresponding respon-sibility to ensure that CS prescriptions are in compli-ance with federal law and regulations, and specifically that they must be dated as of and signed on the day when issued and must include the full name and address of the patient, the drug name, strength, dosage form, quan-tity prescribed, directions for use, and the name, address, and registration number of the practitioner. DEA advises that whether a pharmacist may make changes to a CS II prescription – such as add-ing the practitioner’s DEA number, or correcting the patient’s name or address –

varies case by case based on the facts present. Thus, “DEA expects that when informa-tion is missing from or needs to be changed on a sched-ule II controlled substance prescription, pharmacists use their professional judgment and knowledge of state and federal laws and policies to decide whether it is appro-priate to make changes to that prescription.” DEA also reminds pharmacists and other health care providers to be mindful of dispensing-related activities that violate the Controlled Substances Act (CSA). For example, DEA notes, the following activities are unlawful:

• Intentionally furnish-ing false or fraudulent material information, or omitting material infor-mation from documents required under CSA

•Dispensing a CS pre-scription in violation of requirements for CS Schedule II prescriptions (21 USC 829)

• Knowingly or intention-ally using a registration number that is fictitious, revoked, suspended, expired, or issued to an-other person The letter from DEA

presenting the guidance is available on the NABP Web site at www.nabp.net/news/assets/DEA-missing-info-schedule-2.pdf.

ISMP Issues Safety Alert Regarding Insulin Preparation and Administration

Due to numerous reports of serious errors associated with the misad-

ministration of insulin, the Institute for Safe Medica-tion Practices (ISMP) has issued a medication safety alert explaining the com-mon causes of these errors and presenting safe prac-tice recommendations for avoiding these errors. ISMP notes that human error as-sociated with insulin dose measurement and hyper-kalemia treatment was the predominant proximate cause of these events, and that events have involved various types of health care providers, including physi-cian house officers, nurses, and, in one instance, a pharmacist. Human errors reported were typically “associated with knowledge deficits regarding insulin concentration (specifi-cally that ‘U-100’ means the concentration is 100 units per mL), the differences be-tween insulin syringes and other parenteral syringes, and a perceived urgency with treating hyperkale-mia.” ISMP advises that all health care providers who might prescribe, prepare, and/or administer insulin should receive education in the following areas:

•The concentration of insulin products

•The differences between insulin syringes and other parenteral syringes

•How to measure doses

•Recognition of safe dosage ranges

•How to administer the drugISMP advises further

that preparation and administration of insulin should be restricted to

november-december 2011

223

Association News

•DeAnn Mullins, RPh, has been appointed a member of the Florida Board of Pharmacy. Mul-lins’ appointment will ex-pire on October 31, 2013.

•Lorena Risch has been appointed a public mem-ber of the Florida Board of Pharmacy. Risch’s ap-pointment will expire on October 31, 2014.

•Jill Oliveira Gray, PhD, has been appointed a pub-lic member of the Hawaii State Board of Pharmacy. Oliveira Gray is serving at the discretion of the ap-pointing body.

•Lydia Kumasaka, BSN, MS, APRN, has been ap-pointed a member of the Hawaii State Board of Pharmacy. Kumasaka is serving at the discretion of the appointing body.

•Carolyn Ma, PharmD, has been appointed a member of the Hawaii State Board of Pharmacy. Ma’s appointment will expire on June 30, 2015.

•Robert Haneke, PharmD, RPh, has been appointed a member of the Kansas State Board of Pharmacy. Haneke’s appointment will expire on April 30, 2015.

•Cathy Hanna, PharmD, has been appointed a member of the Kentucky Board of Pharmacy. Hanna’s appointment will expire on January 1, 2015.

•Laura Schwartzwald, RPh, has been appointed a mem-ber of the Minnesota Board

of Pharmacy. Schwartz-wald’s appointment will ex-pire on January 1, 2014.

•Stuart “Stu” Williams, JD, has been appointed a public member of the Minnesota Board of Pharmacy. Wil-liams’ appointment will expire on January 1, 2015.

•Teresa McDaniel, PharmD, has been appointed a mem-ber of the Mississippi Board of Pharmacy. McDaniel’s appointment will expire on June 30, 2015.

•Todd Sandroni, PharmD, has been appointed a mem-ber of the Mississippi Board of Pharmacy. Sandroni’s appointment will expire on June 30, 2014.

•John Westerman, RPh, has been appointed a member of the New York State Board of Pharmacy. Westerman’s appointment will expire on June 30, 2016.

•Diane Halvorson, R. Ph. Tech., has been appointed a member of the North Dako-ta State Board of Pharmacy. Halvorson’s appointment will expire on May 8, 2016.

•Philip McCarthy has been appointed a public mem-ber of the Pennsylvania State Board of Pharmacy. McCarthy is serving at the discretion of the appoint-ing body.

•Vanessa Ballester-Piñan, RPh, has been appointed a member of the Puerto Rico Board of Pharmacy. Ballester-Piñan’s appoint-ment will expire on June 30, 2014.

•Carole Russell, RPh, has been appointed a member of the South Carolina De-partment of Labor, Licens-

Around the Association(continued from page 221)

ing, and Regulation – Board of Pharmacy. Russell’s ap-pointment will expire on June 30, 2017.

•Robert “Crady” Adams, MBA, RPh, has been ap-pointed a member of the Virginia Board of Phar-macy. Adams’ appointment will expire on June 30, 2015.

•Empsy Munden, RPh, has been appointed a member of the Virginia Board of Pharmacy. Munden’s ap-pointment will expire on June 30, 2015.

•Bessie McGirr, RPh, has been appointed a mem-ber of the Wyoming State Board of Pharmacy. Mc-Girr’s appointment will expire on April 1, 2017.

Board Member Reappointments•Edward Maier, RPh, has

been reappointed a member of the Iowa Board of Phar-macy. Maier’s reappoint-ment will expire on April 30, 2014.

•Shirley Arck, PharmD, has been reappointed a member of the Kansas State Board of Pharmacy. Arck’s reap-pointment will expire on April 30, 2012.

•Michael Coast, RPh, has been reappointed a member of the Kansas State Board of Pharmacy. Coast’s reap-pointment will expire on April 30, 2012.

•James Garrelts, PharmD, FASHP, RPh, has been reappointed a member of the Kansas State Board of Pharmacy. Garrelts’ reap-pointment will expire on April 30, 2013.

•Nancy Kirk has been reap-pointed a public member

of the Kansas State Board of Pharmacy. Kirk’s reap-pointment will expire on April 30, 2013.

•William Thompson, RPh, has been reappointed a member of the Missis-sippi Board of Pharmacy. Thompson’s reappoint-ment will expire on June 30, 2015.

•Waymon Tigrett, RPh, has been reappointed a member of the Mississippi Board of Pharmacy. Ti-grett’s reappointment will expire on June 30, 2016.

•Stephen Gross, RPh, has been reappointed an extended member of the New York State Board of Pharmacy. Gross’s reap-pointment will expire on June 30, 2016.

•Rocco Giruzzi, RPh, has been reappointed an extended member of the New York State Board of Pharmacy. Giruzzi’s reap-pointment will expire on June 30, 2016.

•J. Parker Chesson, Jr, PhD, has been reappoint-ed a public member of the North Carolina Board of Pharmacy. Chesson’s reap-pointment will expire on April 30, 2015.

•Robert McLaughlin, Jr, RPh, has been reappointed a member of the North Carolina Board of Phar-macy. McLaughlin’s reap-pointment will expire on April 30, 2016.

•Maria Diaz, RPh, has been reappointed a mem-ber of the Puerto Rico Board of Pharmacy. Diaz’s reappointment will expire on November 16, 2012.

nabp newsletter

224

Association News

Newly Accredited VAWD FacilitiesThe following facilities were accredited through the NABP Verified-Accredited Wholesale Distributors® (VAWD®) program:

A full listing of more than 485 accredited VAWD facilities is available on the NABP Web site at www.nabp.net.

Amerisource Health Services Corporation dba American Health PackagingColumbus, OH

Exel, IncManteno, IL

INO Therapeutics, LLCBolingbrook, ILCoppell, TxPort Allen, LASante Fe Springs, CASomerset, NJSuwannee, GA

J M Smith Corporation dba Smith Drug CompanyValdosta, GA

McKesson Corporation dba McKesson Drug CompanyDelran, NJNew Castle, PA

McKesson Medical-Surgical, IncDenver, CO

Shire, LLCFlorence, KY

Professional Affairs Update(continued from page 222)

NABP InterConnect(continued from page 211)

without the need to use any outside funding sources.

NABP received an unrestricted educational grant from Purdue Phar-ma L.P. in the amount of $1 million. Although not restricted by Purdue in any way, the NABP Foundation® has deter-

mined that this grant will not be used for any costs associated with the devel-opment, implementation, or ongoing operational costs of the NABP Inter-Connect. This grant will be administered through the NABP Foundation, which is a separate nonprofit organization. Funds held by the NABP Foundation are used for special educa-tional or public safety proj-

ects that are separate from and outside NABP’s core programs and activities.

The NABP Founda-tion is making the Purdue unrestricted grant funds available to any state that needs and requests financial assistance to modify its PMP software to participate in the NABP InterConnect. As of Oc-tober 10, 2011, the NABP Foundation has paid

out $203,340 to state PMPs or their software vendors for purposes of connecting individual states via the NABP InterConnect.

Information about the cost and funding of the NABP InterConnect is available in the NABP PMP InterConnect sec-tion of the NABP Web site at www.nabp .net/ programs.

those health care providers who have demonstrated competency in these areas. ISMP also advises that “To preserve an independent double-check, wherever possible, pharmacy should prepare, label, and dis-pense insulin doses to treat hyperkalemia.” More details about the reported errors as well as the de-

tailed safe practice recom-mendations are available in a medication safety alert on the ISMP Web site at www.ismp.org/ Newsletters/acutecare/articles/20110811 .asp.

Clarification Regarding Pradaxa Storage and Handling Requirements

A Food and Drug Ad- ministration (FDA) alert released in March 2011

details important storage and handling guidelines for Pradaxa® (dabigatran etex- ilate mesylate) capsules, as reported in the June-July 2011 NABP Newsletter. As a point of clarification, the FDA-approved Pradaxa la- bel states that once opened, the product must be used within 30 days. FDA is currently reviewing data that indicate no signifi- cant loss of potency up to 60 days after the bottle is opened as long as Pradaxa

is stored in the original bottle and the handling requirements are met. An FDA Drug Safety Commu- nication available at www .fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedical Products/ucm249005.htm provides more details, and the manufacturer’s Pradaxa storage and han- dling information is avail- able at www .pradaxapro .com/storage_handling_ popup.jsp.

november-december 2011

225

In Memoriam Leonard J. “Len” De-

Mino of North Bethesda, MD, passed away on Sep-tember 16, 2011, at the age of 81. DeMino earned his bachelor of science degree in pharmacy from George Washington University. He joined Peoples Drug Stores in Washington, DC, as a staff pharmacist immediately following graduation and worked his way through the ranks to become vice president. DeMino retired in 1989, but soon after joined the National Associa-

tion of Chain Drug Stores (NACDS) as vice president of pharmacy affairs. He retired again in 1991, but continued to serve as a se-nior consultant for NACDS until his official retirement in June 2009.

DeMino was the first chain drug employee ap-pointed to the Maryland Board of Pharmacy, which he served on for 15 years. At that time, he also served on numerous committees at NABP. In 2006, DeMino received the Henry Cade Memorial Award during the

NABP 102nd Annual Meet-ing for his active role in the practice.

Highly active on the academic front, DeMino also served as an instruc-tor in the Department of Pharmacy Practice, College of Pharmacy and Pharmacal Sciences at Howard Univer-sity, and as a member of the Medical College of Virginia School of Pharmacy Advi-sory Board. He was also the first chain drug member of the Accreditation Council for Pharmacy Education and served on its Board of

Directors. In addition, he received several other awards, including the A.H. Robins Bowl of Hy-geia award for communi-ty service in pharmacy in 1972 and the Harold W. Pratt award from NACDS in 1988.

DeMino is survived by his wife, Delores; daughter, Cristina and her hus-band Steve Finney; son, Joseph and his wife Anita DeMino; and his three grandchildren – Catherine and Michael Finney, and Anna DeMino.

Association News

State Board News(continued from page 221)

• Immediately notify the retailer if a sale will exceed legal limits

• Allow the retailer to over-ride the stop-sale alert if the retailer is in reasonable fear of imminent bodily harm

• Be accessible to law en-forcement for investigative purposesAdditional information

about the implementation of the law is available on the Board’s Web site at www.doh .wa.gov/hsqa/Professions/Pharmacy/NPLEx.htm.

NY Board Announces Extension of Immunization Law

The New York State Board of Pharmacy reports that

Governor Andrew Cuomo signed legislation effectively extending the statute au-thorizing New York State’s pharmacists to administer influenza and pneumococ-cal vaccinations until March 31, 2016. The law, enacted in December 2008, had been scheduled to “sunset” on March 31, 2012.

The Board reports that since the initial implemen-tation of the law, many pharmacists have become certified to administer immunizations, and the Board is encouraged that pharmacists have made a dramatic impact on rates of immunization in the state. By August 2011, more than 6,200 pharmacists were certified, with that number expected to grow to more than 7,000 by the end of the year.

The Board also notes that there is strong support for expanding the immu-nization law to authorize New York pharmacists to administer all Centers for Disease Control and Pre-vention (CDC)-approved vaccines in adult doses, to extend the provision to qualified pharmacy interns, and to remove the county-by-county requirement for standing orders. CDC has reported significant increases in New York’s immunization rates, espe-cially among traditionally underserved communities, and the state’s legislature awaits the release of a required New York State Department of Health re-port on the impact of im-munization by pharmacists before a decision regarding amending the law is made.

AL Board Code of Professional Conduct Forbids Prescription Transfer Incentives

The Alabama State Board of Pharmacy’s Code of Professional Conduct was amended effective June 6, 2011, to add language stating that a pharmacist should never offer or par-ticipate in the offering of a financial award or benefit, not related to competitive retail pricing of any drug, to induce or encourage any individual to transfer a pre-scription from one phar-macy to another.

To view the Board’s amended Code of Profes-sional Conduct in its entirety, visit the Statutes and Rules section on the Alabama State Board of Pharmacy’s Web site at www.albop.com.

nabp newsletter

226

Index Volume 40

107th Annual Meeting107th Annual Meeting Educational Poster

Session Offers Attendees Opportunity to Earn CPE Credit, Chance to Interact with Presenters (SI, pg 18)

107th Annual Meeting Travel Grants Avail-able for Qualified Board of Pharmacy Voting Delegates (Feb, No. 2‚ pg 39)

2011-2012 Executive Committee Inaugu-rated at 107th Annual Meeting (SI, pg 3)

2011-2012 NABP Executive Committee Nominees Announced; Elections to Take Place During Upcoming 107th Annual Meeting (Jan, No. 1‚ pg 3)

Acclaimed NASA Scientist Steven Squyres Shares What it Takes to Reach Mars, and Other Goals, During Annual Meeting Keynote (Feb, No. 2‚ pg 37)

Celebrate the Unique Culture of San An-tonio During the NABP 107th Annual Meeting Optional Events (Mar, No. 3‚ pg 61)

Convenient Online Annual Meeting Reg-istration to be Available February 2011 through NABP Web Site (Feb, No. 2‚ pg 37)

Educational Sessions Explore Current Issues Affecting Pharmacy Practice (SI, pg 16)

Federal Regulatory Agencies and Other Or-ganizations Provide Educational Table Displays to Highlight Important Issues and Programs (SI, pg 14)

Five Resolutions Approved by Board of Pharmacy Delegates During NABP 107th Annual Meeting (SI, pg 4)

March Deadline Approaching for NABP 107th Annual Meeting Poster Session Participants to Reserve a Spot (Feb, No. 2‚ pg 39)

Meeting Program (Jan, No. 1‚ pg 12; Feb, No. 2‚ pg 38; Mar, No. 3‚ pg 62; Apr, No. 4‚ pg 80; May, No. 5, pg 103)

NABP 107th Annual Meeting Highlights Opportunities for Building to Unity and Strength; Business and CPE Ses-sions Pave the Way (SI, pg 1)

NABP 107th Annual Meeting Offers Par-ticipants Opportunity to Earn Nine Hours of Continuing Pharmacy Edu-cation Credit (Apr, No. 4‚ pg 81)

NABP Accepting Annual Meeting Travel Grant Applications (Mar, No. 3‚ pg 63)

NABP Continues to Accept Travel Grant Applications for the 107th Annual Meeting in San Antonio, Tx (Apr, No. 4‚ pg 82)

NABP Honors Leaders at the Forefront of Public Health Protection (SI, pg 12)

NABP Officer Reports Provide Detailed Look at State of Association (SI, pg 9)

NABP to Honor Leaders at the Forefront of Public Protection During 107th Annual Meeting in San Antonio (May, No. 5, pg 95)

Poster Session Deadline Approaching for 107th Annual Meeting (Mar, No. 3‚ pg 63)

Poster Session Participants Sought for NABP 107th Annual Meeting (Jan, No. 1‚ pg 15)

Proposed Resolution Advanced Distribution Set for March 2011 (Jan, No. 1‚ pg 14)

Register Online Today for the NABP 107th Annual Meeting (Mar, No. 3‚ pg 63; Apr, No. 4‚ pg 82)

San Antonio History, Culture to Set Scene for 2011 Annual Meeting (Jan, No. 1‚ pg 13)

Special CPE Session Speakers Provide Phar-macy Practice Insights from Around the Globe (SI, pg 6)

Special Hotel Room Rates Available Now for 107th Annual Meeting (Jan, No. 1‚ pg 14)

Sponsorships and Grants Provide Support for Annual Meetings (SI, pg 15)

Travel Grant Applications Still Being Ac-cepted for Annual Meeting (May, No. 5, pg 102)

Travel Grants Available for Boards’ Quali-fied Voting Delegates to Attend 107th An-nual Meeting in San Antonio (Jan, No. 1‚ pg 15)

108th Annual MeetingDeadline Announced to Submit Proposed

Amendments to the NABP Constitution and Bylaws (Nov-Dec, No. 10, pg 220)

Nominees Sought for 2012 Awards to be Presented at the NABP 108th Annual Meeting in Philadelphia (Oct, No. 9, pg 197)

Save the Date! (Nov-Dec, No. 10, pg 232)Sponsorship and Educational Grant

Opportunities for NABP 108th Annual Meeting Now Available (Nov-Dec, No. 10, pg 220)

AccreditationAccreditation: An Essential Distinction in

the Evolving Realm of Pharmacy (Mar, No. 3‚ pg 52)

CMS DMEPOS Competitive Bidding Program Now in Effect; Round 2 to Include 91 Metropolitan Statistical Areas (Mar, No. 3‚ pg 64)

DMEPOS Accreditation Exemptions Clarified by CMS (Feb, No. 2‚ pg 31)

Newly Accredited DMEPOS Facilities (Jan, No. 1‚ pg 18; Feb, No. 2‚ pg 44; Mar, No. 3‚ pg 64; Apr, No. 4‚ pg 88; May, No. 5, pg 94; Aug, No. 7, pg 160; Sep, No. 8, pg 172; Oct, No. 9, pg 192; Nov-Dec, No. 10, pg 225)

Newly Approved e-Advertisers (Jan, No. 1‚ pg 17; Mar, No. 3‚ pg 50; Apr, No. 4‚ pg 79; May, No. 5, pg 111; Aug, No. 7, pg 158; Nov-Dec, No. 10, pg 219)

Newly Accredited VAWD Facilities (Jan, No. 1, pg 24; Feb, No. 2‚ pg 43; Mar, No. 3‚ pg 59; Apr, No. 4‚ pg 75; Aug, No. 7, pg 159; Sep, No. 8, pg 166; Oct, No. 9, pg 190; Nov-Dec, No. 10, pg 224)

Newly Accredited Vet-VIPPS Facility (Feb, No. 2‚ pg 42; Mar, No. 3‚ pg 50; Jun-Jul, No. 6, pg 136; Sep, No. 8, pg 174)

Newly Accredited VIPPS Facilities (Jan, No. 1, pg 6; Apr, No. 4‚ pg 85; Oct, No. 9, pg 200)

Around the AssociationAPhA Honors Past NABP Executive Com-

mittee Member (Jun-Jul, No. 6, pg 133)NABP Staff Train for CPR/AED Certifica-

tion (Feb, No. 2, pg 35)NABP Thanks All who Participated in

Newsletter Survey (Feb, No. 2‚ pg 41)Wyoming Board Staff Meets Update Dead-

line, Wins Survey Luncheon Drawing (Oct, No. 9, pg 204)

Board Member Appointments

Adams, Greg (Sep, No. 8, pg 181)Adams, Robert “Crady” (Nov-Dec, No. 10,

pg 223)Ballester-Piñan, Vanessa (Nov-Dec, No. 10,

pg 223)Baumgartner, Shirley (Sep, No. 8, pg 181)Bird‚ Janice (Apr, No. 4‚ pg 87)Blomstrom‚ Cheryl (Feb, No. 2‚ pg 35)Burch‚ Clovis (Jan, No. 1‚ pg 19)Chute‚ Christine (Apr, No. 4‚ pg 87)Dartez‚ Ryan (Jan, No. 1‚ pg 19)Dudley, Stephen (Sep, No. 8, pg 181)Feild, Donna (Jun-Jul, No. 6, pg 134)Gratias, LaDonna (Aug, No. 7, pg 156)Halvorson, Diane (Nov-Dec, No. 10, pg 223)Haneke, Robert (Nov-Dec, No. 10, pg 223)Hanna, Cathy (Nov-Dec, No. 10, pg 223)Ho‚ Elizabeth (Jan, No. 1‚ pg 19)Indovina‚ Jr‚ Richard (Jan, No. 1‚ pg 19)

*SI = Special Issue

november-december 2011

227

Index Volume 40

Jensen, Elizabeth (Jun-Jul, No. 6, pg 134)Jones‚ Gregory (Apr, No. 4‚ pg 87)Kemper‚ Andrea (Apr, No. 4‚ pg 87)Kumasaka, Lydia (Nov-Dec, No. 10, pg 223)Lewis‚ Jody (Feb, No. 2‚ pg 35)Lieberman‚ Stephen (Feb, No. 2‚ pg 35)Lundberg‚ Kelly (Apr, No. 4‚ pg 87)Ma, Carolyn (Nov-Dec, No. 10, pg 223)Mala, Theodore (Nov-Dec, No. 10, pg 221)McCarthy, Philip (Nov-Dec, No. 10, pg 223)McConaghy‚ Dan (Mar, No. 3‚ pg 65)McDaniel, Teresa (Nov-Dec, No. 10, pg 223)McGirr, Bessie (Nov-Dec, No. 10, pg 223)Mesaros, Jeffrey (Nov-Dec, No. 10, pg 221)Meshad, Gavin (Nov-Dec, No. 10, pg 221)Miller, James (Jun-Jul, No. 6, pg 134)Mitchell, Kevin (Jun-Jul, No. 6, pg 134)Mullins, DeAnn (Nov-Dec, No. 10, pg 223)Munden, Empsy (Nov-Dec, No. 10, pg 223)Musil‚ John (Feb, No. 2‚ pg 35)Oliveira Gray, Jill (Nov-Dec, No. 10, pg 223)Rave‚ Lisa (Feb, No. 2‚ pg 35)Reed‚ Pamela (Jan, No. 1‚ pg 19)Reher, Penny (Oct, No. 9, pg 203)Risch, Lorena (Nov-Dec, No. 10, pg 223)Rosas‚ Nona (Feb, No. 2‚ pg 35)Russell, Carole (Nov-Dec, No. 10, pg 223)Schwartzwald, Laura (Nov-Dec, No. 10, pg

223)Sandroni, Todd (Nov-Dec, No. 10, pg 223)Simonson‚ Deborah (Jan, No. 1‚ pg 19)Shah‚ Mahesh (Feb, No. 2‚ pg 35)Smith‚ Russell (Feb, No. 2‚ pg 35)Smothers‚ Nina (Jan, No. 1‚ pg 19)Sosnowski‚ Frank (Feb, No. 2‚ pg 35)Sulli‚ Maria (Feb, No. 2‚ pg 35)Weinert‚ Ronald (Mar, No. 3‚ pg 65)Westerman, John (Nov-Dec, No. 10, pg 223)Williams, Stuart “Stu” (Nov-Dec, No. 10,

pg 223)

Board Member Reappointments

Arck, Shirley (Nov-Dec, No. 10, pg 223)Carlson‚ Dale (Jan, No. 1‚ pg 20)Chesson, Jr, J. Parker (Nov-Dec, No. 10, pg

223)Coast, Michael (Nov-Dec, No. 10, pg 223)Davis, Robert (Jun-Jul, No. 6, pg 134)Diaz, Maria (Nov-Dec, No. 10, pg 223)Duteau‚ Michael (Mar, No. 3‚ pg 65)Fraser, Berk (Oct, No. 9, pg 203)Garrelts, James (Nov-Dec, No. 10, pg 223)Giruzzi, Rocco (Nov-Dec, No. 10, pg 223)

Gross, Stephen (Nov-Dec, No. 10, pg 223)Kirk, Nancy (Nov-Dec, No. 10, pg 223)Haroldson‚ Laurel (Jan, No. 1‚ pg 20)Henggeler‚ Holly (Mar, No. 3‚ pg 65)Maier, Edward (Nov-Dec, No. 10, pg 223)McLaughlin, Robert (Nov-Dec, No. 10, pg

223)Molino‚ Daniel (Mar, No. 3‚ pg 65)McPherson, John (Jun-Jul, No. 6, pg 134)Newsome‚ Lenora (Jan, No. 1‚ pg 20)Pimlott‚ Dianna (Apr, No. 4‚ pg 87)Schmidt‚ Harvey (Jan, No. 1‚ pg 20)Senneker‚ Devin (Jan, No. 1‚ pg 20)Thompson, William (Nov-Dec, No. 10, pg

223)Tigrett, Waymon (Nov-Dec, No. 10, pg 223)Wedemeyer Oleson‚ DeeAnn (Jan, No. 1‚ pg 20)Wheat, Shirley (May, No. 5, pg 111)White, Dirk (Jun-Jul, No. 6, pg 134)Whitworth‚ Margaret (Jan, No. 1‚ pg 20)

Board Officer Changes

Adams‚ Patrick (Jan, No. 1‚ pg 20)Beckner‚ John (Jan, No. 1‚ pg 20)Brown‚ Mark (Jan, No. 1‚ pg 20)Bryant, Steve (Oct, No. 9, pg 203)Calhoun, Donnie (May, No. 5, pg 111)Carr, Terry (Aug, No. 7, pg 156)Cartier, Larry (May, No. 5, pg 111)Casar‚ Donald (Jan, No. 1‚ pg 20)DeRose, Jr, Dominic (May, No. 5, pg 111)Detwiller‚ Rick (Jan, No. 1‚ pg 20)Fanaras‚ Charles (Jan, No. 1‚ pg 20)Haiber, Steven (May, No. 5, pg 111)Harrop, Randolph (Aug, No. 7, pg 156)Hill‚ Albert (Jan, No. 1‚ pg 20; May, No. 5,

pg 111)Kajioka, Randy (May, No. 5, pg 111)Kolezynski‚ Richard (Jan, No. 1‚ pg 20) Manoukian‚ Vahrij (Jan, No. 1‚ pg 20)McPherson, John (Aug, No. 7, pg 156)Milovich, Daniel (May, No. 5, pg 111)Nelson, Robert (May, No. 5, pg 111)Norris‚ Ronald (Jan, No. 1‚ pg 20; Oct, No.

9, pg 203)Osborn‚ William (Jan, No. 1‚ pg 20)Petrin‚ Ronald (Jan, No. 1‚ pg 20)Post‚ Benji (Jan, No. 1‚ pg 20)Richards‚ Gordon (Jan, No. 1‚ pg 20)Sitzes‚ Marilyn (Jan, No. 1‚ pg 20; Oct, No.

9, pg 203)Warren, Brenda (May, No. 5, pg 111)Weisser, Stanley (May, No. 5, pg 111)

Wilson‚ Bettie (Jan, No. 1‚ pg 20)Yi‚ Brandon (Jan, No. 1‚ pg 20)Zweber, Ann (May, No. 5, pg 111)

Executive Officer Changes

Jones, Randy (Aug, No. 7, pg 156)Juran, Caroline (Jun-Jul, No. 6, pg 134)Kirtley, John (Oct, No. 9, pg 203)Stewart, Jay (Nov-Dec, No. 10, pg. 221)Whitten, Mark (Jun-Jul, No. 6, pg 133)

AWARxEAre You AWARxE? (Feb, No. 2‚ pg 26; Apr,

No. 4‚ pg 74; May, No. 5, pg 102; Jun-Jul, No. 6, pg 126; Aug, No. 7, pg 151; Sep, No. 8, pg 178)

Arizona Pharmacy Foundation Raises AWARxEness About Prescription Drug Abuse and Safe Drug Disposal (Oct, No. 9, pg 200)

AWARxE Across America – Learn How Your Board Can Get Involved (Nov-Dec, No. 10, pg 218)

AWARxE Gets the Word Out on the Street with New Ad Campaign (Aug, No. 7, pg 158)

AWARxE Minnesota Campaign Helps Drug Enforcement Administration and Informs Students of Drug Dangers (Jan, No. 1‚ pg 23)

AWARxE National Campaign Encourages Proper Disposal of Prescription Drugs to Prevent Diversion and Abuse (Oct, No. 9, pg 201)

NABP to Discuss Pharmacist Competence, AWARxE During 2011 APhA Meeting (Feb, No. 2‚ pg 26)

New AWARERx.ORG Content to Educate Consumers on Prescription Drug Abuse and Medication Safety (Mar, No. 3‚ pg 50)

Competency Assessment 2011-2012 FPGEE Review Committee Mem-

bers Announced (May, No. 5, pg 107)2011-2012 MPJE Review Committee An-

nounced (Mar, No. 3‚ pg 46)2011-2012 NAPLEx Review Committee

Members Announced (Apr, No. 4‚ pg 84)2012 PCOA Administration Approaching in

January, New Computer-Based Format to be Available (Nov-Dec, No. 10, pg 219)

April 2011 FPGEE Administration Ap-proaches (Feb, No. 2‚ pg 30)

Candidates Register for NAPLEx, MPJE with Upgraded System and More Regis-tration Features (Jun-Jul, No. 6, pg 115)

*SI = Special Issue

nabp newsletter

228

Index Volume 40

Foreign Pharmacy Graduate FPGEE and NAPLEx Pass Rate Trends (Jun-Jul, No. 6, pg 129)

FPGEE Competency Statements and Blue-print Updated (Nov-Dec, No. 10, pg 214)

Item Writers Needed to Develop New Test Questions for NAPLEx, MPJE, FPGEE, and PCOA (Aug, No. 7, pg 154)

NABP Moving to New Linear Test Form Assembly Process to Enhance Asso-ciation’s Examination Programs (Nov-Dec, No. 10, pg 219)

NABP Encourages Use of NAPLEx/MPJE Online Score Reporting (Feb, No. 2‚ pg 36)

NABP Seeks Member Board of Pharmacy Applicants to Serve on the Advisory Committee on Examinations (Oct, No. 9, pg 196)

NAPLEx, MPJE, and FPGEE Administra-tions Increase in 2010 (Mar, No. 3‚ pg 51)

New and Improved NAPLEx/MPJE Applica-tion Coming Soon (Feb, No. 2‚ pg 36)

Openings Available for Volunteers to Serve on NAPLEx, MPJE, FPGEE, and PCOA Review Committees (May, No. 5, pg 107)

PCOA Administration Continues to Dem-onstrate Students’ Progression of Knowl-edge through Program Years (Jun-Jul, No. 6, pg 128)

Registration Now Open for the 2012 PCOA Administration: Schools and Colleges of Pharmacy Encouraged to Participate (Sep, No. 8, pg 169)

Revisions to MPJE Competencies (Jan, No. 1‚ pg 16)

School of Pharmacy Study Finds Value in PCOA as Integral Component of Stu-dent and Curricular Assessment (Apr, No. 4‚ pg 75)

Technological Challenges Delay Start of April 2011 FPGEE Administration, Pear-son VUE Reports (Jun-Jul, No. 6, pg 134)

Three New Members Appointed to Serve on the 2011-2012 Advisory Committee on Examinations (Jun-Jul, No. 6, pg 131)

Two New States Require MPJE (Jan, No. 1‚ pg 16)

CPE MonitorACPE-Accredited Providers Participate in

CPE Monitor Pilot, Begin to Require NABP e-Profile ID for CPE Credit Submission (Nov-Dec, No. 10, pg 215)

CPE Monitor Service Advances with Support from Boards of Pharmacy (Oct, No. 9, pg 199)

CPE Monitor Service Pilots Data Exchange Processes, Pharmacists and Technicians Continue to Create e-Profiles in Prepara-tion (Aug, No. 7, pg 150)

Launch of CPE Monitor to Streamline Re-porting of Continuing Pharmacy Edu-cation Activity, Saving Boards Time and Resources (Apr, No. 4‚ pg 83)

Participants Prepare to Use CPE Monitor Service (May, No. 5, pg 91)

Pharmacist and Technician Unique Identifi-ers Necessary to Assist in Ensuring Accu-racy of CPE Monitor e-Profiles (Jun-Jul, No. 6, pg 130)

Errata Clarification (Mar, No. 3‚ pg 60)

Legal Briefs107th Annual Meeting Report of Counsel:

Catch Me If You Can (Jun-Jul, No. 6, pg 116)

Canadian DisConnection (Feb, No. 2‚ pg 28)Certifican’t Can (Oct, No. 9, pg 188)Citizenship Kane (Jan, No. 1‚ pg 4)FTC: Facinorous Teeth Case (Aug, No. 7, pg

140)Hey Mabel, Another Generic Label (Sep, No.

8, pg 164)If It Walks Like a Florida Nurse and Quacks

Like a Massachusetts Physician, It Must Be a Massachusetts Nurse (Apr, No. 4‚ pg 72)

I.N.S.P.E.C.T. . . . Find Out What It Means To Me (May, No. 5, pg 92)

Judicial Branch, Executive Branch, Olive Branch (Mar, No. 3‚ pg 48)

School Gets In Your Facebook (Nov-Dec, No. 10, pg 208)

Licensure 2010 NABP Clearinghouse Results Dem-

onstrate National Trends in Disciplinary Actions Reported by Boards (Mar, No. 3‚ pg 57)

Boards Report 846 Disciplinary Actions in Third Quarter (Nov-Dec, No. 10, pg 213)

Boards Report 1,003 Disciplinary Actions in Second Quarter (Sep, No. 8, pg 175)

NABP Clearinghouse Sees More Than 100% Increase in Disciplinary Actions Report-ed by Boards of Pharmacy During First Quarter (Jun-Jul, No. 6, pg 125)

NABP ELTP Celebrates 15 Years of Facili-tating Streamlined Licensure Transfer for Boards and Pharmacists (Jan, No. 1‚ pg 17)

Requests for License Transfer Continue to Climb Following High National Demand for Pharmacists (Mar, No. 3‚ pg 55)

NABP – General2012 Survey of Pharmacy Law Available in

December (Nov-Dec, No. 10, pg 220)Annual Report of Counsel on Association

Legal Affairs (Jun-Jul, No. 6, pg 121)Board of Pharmacy Role in ADA Testing

Accommodations (Sep, No. 8, pg 173)Board of Pharmacy Staff, New Execu-

tive Officers Invited to Attend Annual Training on NABP Programs and Ser-vices (May, No. 5, pg 99)

Community Pharmacy Accreditation Program to Help Analyze Effective-ness of Pharmacies’ CQI Programs (Jan, No. 1‚ pg 8)

Counterfeit Drugs Distributed Via Internet Endanger Unsuspecting Pa-tients; NABP Reports on Progress in Fighting Rogue Sites (Nov-Dec, No. 10, pg 212)

Counterfeit Drugs Remain a Threat to Public Health Protection as Distribution Thrives through Rogue Internet Drug Outlets (Sep, No. 8, pg 176)

Customizable Inspection and Compliance Assistance Services Now Available for Boards of Pharmacy (Apr, No. 4‚ pg 71)

Emergency Preparedness Resources (Sep, No. 8, pg 183)

Global Threat of Counterfeit Drugs Gain Exposure; NABP Quarterly Progress Report Highlights Actions Taken (Jun-Jul, No. 6, pg 127)

Legal Use of SSNs by Private Entities, In-cluding NABP (Jun-Jul, No. 6, pg 130)

Members Sought for 2011-2012 NABP Committees and Task Forces (Jan, No. 1‚ pg 16)

Model Act Amended to Stay at Forefront of Pharmacy Practice Regulations (Sep, No. 8, pg 163)

NABP Accreditation Program Surveyors Contribute Vast Range of Expertise to Boards of Pharmacy Nationwide (Oct, No. 9, pg 195)

NABP Begins Developing System to Fa-cilitate PMP Data Exchange Across State Lines (Feb, No. 2‚ pg 25)

NABP Government Affairs Department Supports Vermont Board’s Efforts to Increase Operations Efficiency (Jun-Jul, No. 6, pg 123)

*SI = Special Issue

november-december 2011

229

Index Volume 40

NABP Government Affairs Offers Cus-tomizable Services to Boards (Aug, No. 7, pg 150)

NABP Government Affairs Identifies New Opportunities for Assisting State Boards (Mar, No. 3‚ pg 47)

NABP Hosts Annual Program Review and Training to Inform Board of Phar-macy Staff, New Executive Officers (Sep, No. 8, pg 177)

NABP Joins Other Stakeholders at White House to Discuss Fighting Rogue In-ternet Drug Sites and Counterfeit Drugs (Jan, No. 1‚ pg 7)

NABP Launches Web-Based Interface to Assist Boards of Pharmacy in Report-ing Facility Issues to HIPDB (Mar, No. 3‚ pg 59)

NABP Newsletter Celebrates 75 Years of Informing Members (Apr, No. 4‚ pg 84)

NABP PMP InterConnect Development Complete; Participating PMPs Partner with NABP to Finalize Implementa-tion (Aug, No. 7, pg 139)

NABP PMP InterConnect Development Complete; Piloting of Data Exchange Anticipated for Late July 2011 (Jun-Jul, No. 6, pg 131)

NABP PMP InterConnect Steering Com-mittee Finalizes Governance Structure and Policies (Nov-Dec, No. 10, pg 211)

NABP President Appoints Members to Serve on 2011-2012 Committees and Four Single-Issue Task Forces (Oct, No. 9, pg 193)

NABP Uncovers More Rogue Internet Drug Outlets Operating in Conflict with Pharmacy Laws and Practice Standards (Jan, No. 1‚ pg 18)

Patient Safety Stakeholders Mark Progress Made in 2010 to Weaken Rogue Inter-net Drug Sellers, Promise Continued Efforts in 2011 (Mar, No. 3‚ pg 60)

PMP Interconnect Pilot to Launch (Mar, No. 3‚ pg 45)

Rogue Internet Drug Outlets Fuel Na-tional Problem of Prescription Drug Abuse and Misuse, Poisonings, and Fatalities (Aug, No. 7, pg 152)

Task Force Recommends CSA Revisions Aimed to Support Patient Care and Safety (Jun-Jul, No. 6, pg 113)

Task Force to Review Laws, Regulations, and Issues Related to Control and Ac-countability of Prescription Medica-tions (Sep, No. 8, pg 167)

Task Force to Review Laws, Regulations for Safe Use of Pharmacy Technology Systems (Oct, No. 9, pg 185)

Three PMPs Now Using NABP InterCon-nect to Treat Patients and Track Drug Use (Oct, No. 9, pg 187)

NABP Interactive ForumsBoard of Pharmacy Executive Officers Share

Successes, Challenges at Interactive Fo-rum (Nov-Dec, No. 10, pg 205)

Compliance Officers, Investigators, Inspec-tors, and Surveyors to Convene (Oct, No. 9, pg 195)

Executive Officer Forum Panelists Lead Dis-cussions on Common Issues Faced by the State Boards of Pharmacy (Nov-Dec, No. 10, pg 216)

Meet NABP Government Affairs Staff Dur-ing Interactive Forums (Sep, No. 8, pg 176)

Prescription for Shared Future: The Part-nering Plan to Protect Public Health through AWARxEness (Aug, No. 7, pg 143)

Pharmacy – General

Boards of Pharmacy Take Actions to Sup-port Pharmacists’ Emergency Response Efforts (Sep, No. 8, pg 161)

Boards of Pharmacy, State Legislators, and Law Enforcement Continue to Tackle Methamphetamine Problem (May, No. 5, pg 96)

Conscience Clause Controversy on Back Burner, but Still Simmering (Apr, No. 4‚ pg 76)

Drug Disposal Act Signed into Law to Lessen Opportunities for Controlled Substance Diversion and Abuse (Jan, No. 1‚ pg 11)

Drug Disposal Programs and PMPs Con-tinue to Play Vital Role in Fighting Pre-scription Drug Abuse (Feb, No. 2‚ pg 27)

FDA to Release Guidance Document on Ap-proval Pathway for Biosimilars (Nov-Dec, No. 10, pg 207)

Idaho Grants Pharmacists Limited Pre-scriptive Authority, Amends Definition of ‘Drug Outlet’ to Expand Regulatory Authority (Oct, No. 9, pg 191)

Medication Error Reporting: CQI Programs Offer Avenue to Vital Follow-Up (Jan, No. 1‚ pg 1)

National, International Stakeholders De-velop New Strategies for Fighting Coun-terfeit Drugs (May, No. 5, pg 89)

New Strategies in Preventing Acetamino-phen Overdose Aim to Empower Pa-tients (Sep, No. 8, pg 170)

New Tools Aid Community Pharmacists in Preventing Adverse Drug Events (Aug, No. 7, pg 146)

Paving Approval Pathway for Biosimilars Presents Unique Challenges for FDA (Apr, No. 4‚ pg 69)

PCAB Achieves Milestone in Accredita-tion Numbers (May, No. 5, pg 106)

Pharmacogenomics: Personalized Drug Therapy Can Reduce ADEs (Aug, No. 7, pg 148)

Regulations Impact Pharmacist Coun-seling Activities for Benefit of Patient Health (Feb, No. 2‚ pg 32)

Shutting Down Illegal Pain Clinics: New State Legislation to Support Multifac-eted Efforts (Aug, No. 7, pg 144)

States, FDA Pressing Forward with Pedi-gree, Track and Trace Rules and Regula-tions (May, No. 5, pg 101)

Third DEA National Prescription Drug Take-Back Day in October (Oct, No. 9, pg 201)

White House Implements Plan to Fight Abuse of Prescription Opioids and Other Medications (Aug, No. 7, pg 137)

PhotosAbeldt, Sr, Buford (May, No. 5, pg 108)Adams, Joseph (Apr, No. 4, pg 85; SI, pg 11;

Nov-Dec, No. 10, pg 217)Allen, Lloyd (Sep, No. 8, pg 181)Anderson, Jr, Howard C. (Nov-Dec, No.

10, pg 217)Anderson, Wendy (May, No. 5, pg 108)Apple, Kathy (Mar, No. 3, pg 67)Arnold, Kerstin (SI, pg 15)Aron‚ Carl W. (Apr, No. 4, pg 85)Atkinson‚ Dale J. (Jan, No. 1‚ pg 5; Feb, No.

2, pg 29; Mar, No. 3, pg 49; Apr, No. 4, pg 73; May, No. 5, pg 93; Jun-Jul, No. 6, pg 117; SI, pg 16; Aug, No. 7, pg 141; Sep, No. 8, pg 165; Oct, No. 9, pg 189)

Baney, Libby (SI, pg 17)Barton, Paula (Mar, No. 3, pg 67)Baumgartner, Jennifer (SI, pg 14)Beall, Jennifer (Mar, No. 3, pg 51; Sep, No.

8, pg 181)Becker, Shawn (SI, pg 15)Bess‚ Todd (Apr, No. 4‚ pg 85)Boggs, Gary (SI, pg 16)Bolin, Joshua (SI, pg 14; SI, pg 16; Nov-Dec,

No. 10, pg 217)

*SI = Special Issue

nabp newsletter

230

Index Volume 40

Braylock, Sr, Gregory (SI, pg 17)Brickley‚ Ross (Apr, No. 4‚ pg 70)Broadway‚ Myra (Mar, No. 3, pg 67)Broussard, Malcolm J. (Mar, No. 3, pg 67;

SI, pg 3; SI, pg 16)Bundrick, Lee Ann (May, No. 5, pg 108)Burgess, Philip P. (May, No. 5, pg 108)Burleson, Michael A. (SI, pg 3; SI, pg 20;

Sep, No. 8, pg 184)Bush‚ Freda (Mar, No. 3, pg 67)Caldwell, Kim A. (SI, pg 12)Campbell‚ Jay (Apr, No. 4‚ pg 70)Carter, Caitlin (SI, pg 18)Catizone‚ Carmen A. (Mar, No. 3, pg 67)Chapman, Phyllis (Oct, No. 9, pg 204)Chaudhry‚ Humayun “Hank” (Mar, No. 3, pg 67)Cheung, Grace (Aug, No. 7, pg 159)Conforti‚ Brandon (Mar, No. 3, pg 67)Conrad, Ariane (Jan, No. 1, pg 10)Conradi, Mark T. (SI, pg 10)Cover, William (Mar, No. 3, pg 67; May, No.

5, pg 108; SI, pg 10)Cruz-Tapia, Rocio (Sep, No. 8, pg 177)D’Antonio‚ Patricia (Apr, No. 4‚ pg 70)DelMonico, Susan (May, No. 5, pg 108)DeVita‚ James T. (Mar, No. 3, pg 67; SI, pg 10)Dodson, Gay (Nov-Dec, No. 10, pg 216)Donato, Patricia (May, No. 5, pg 108)Dong, Betty (Apr, No. 4, pg 85)Dover, Kristi (Apr, No. 4‚ pg 70)Droz, Danna (Apr, No. 4‚ pg 70)Duteau‚ Michael (Apr, No. 4‚ pg 85)Fisher, Carol E. (SI, pg 13; SI, pg 19)Fontaine, Beverly (Oct, No. 9, pg 204)Gammill, Frank (Nov-Dec, No. 10, pg 216)Gehrmann, Erika (SI, pg 14)Gibbons, Moira (Nov-Dec, No. 10, pg 216)Gozun, Edisa (SI, pg 17)Guse, Ron (Nov-Dec, No. 10, pg 216)Ha‚ Carolyn (Mar, No. 3, pg 67)Hatfield, Ron (SI, pg 14)Herold, Virginia (Apr, No. 4‚ pg 70; Nov-

-Dec, No. 10, pg 216)Holder, Paul (SI, pg 19)Horn, Donna (SI, pg 20)Jacknowitz‚ Arthur I. (Apr, No. 4, pg 85)Jessen, Lloyd K. (SI, pg 11; SI, pg 17; Nov-Dec,

No. 10, pg 217)Jones, Randy (Sep, No. 8, pg 184)Jons, Joshua (Oct, No. 9, pg 204)Juran, Caroline (Sep, No. 8, pg 184; Nov-

-Dec, No. 10, pg 216)Kedron‚ Suzan (Apr, No. 4‚ pg 70)

Kehoe, William (Mar, No. 3, pg 51)Khan, Omar F. (Jan, No. 1, pg 10)Kolezynski, Richard F. (SI, pg 13)Ksiazek, Susan (Apr, No. 4‚ pg 70; SI, pg 12)Kyle, Jeffrey (Jan, No. 1, pg 10)Levendoski, Wanda (SI, pg 19)Levine, Gertrude (SI, pg 17)Lew‚ Cathryn (Apr, No. 4‚ pg 70; SI, pg 11)Lewis, Ann (SI, pg 16)Luce, Dan (Mar, No. 3, pg 67)Mack‚ Debbie (Mar, No. 3, pg 67)Mazza‚ Scott (Mar, No. 3, pg 67)McAllister, Dennis K. (SI, pg 20)McGinley, Edward G. (SI, pg 10; SI, pg 16;

Nov-Dec, No. 10, pg 217)McInerney, Gerard (SI, pg 16)McKay, Michelle (SI, pg 18)Mokhiber‚ Lawrence (Apr, No. 4‚ pg 70; SI,

pg 20; Nov-Dec, No. 10, pg 217)Morrison‚ Richard (Apr, No. 4, pg 85; Aug,

No. 7, pg 159)Nasr, Samia M. (SI, pg 17)Neuber‚ Suzanne (Apr, No. 4‚ pg 70)Nicholson‚ Kevin (Mar, No. 3, pg 67)Oster, Kim (Sep, No. 8, pg 177)Palombo‚ Rich (Mar, No. 3, pg 67; SI, pg 20)Peacock, Oren M. (SI, pg 20)Plorin, Rosemary (SI, pg 17)Podgurski‚ Michael (Mar, No. 3, pg 67)Poole, Barry (SI, pg 14)Richard‚ Brian (Mar, No. 3, pg 67)Rouse, Michael (SI, pg 14)Russell, Elizabeth Scott (SI, pg 14)Ryle, Karen M. (SI, pg 10; Nov-Dec, No. 10,

pg 216)Ryan, Mary J. (SI, pg 13)Rynn‚ Kevin (Apr, No. 4, pg 85)Salazar, Theresa (Jan, No. 1, pg 10)Sauer, Charles W. (Aug, No. 7, pg 159)Schnatz, Rick (SI, pg 15)Schabel, Gary A. (SI, pg 20)Schneider, Eric (May, No. 5, pg 106)Seeburg-Elverfeldt, Niels J. (SI, pg 16)Sheahan, Megan (SI, pg 15)Shepley, Alan M. (Aug, No. 7, pg 159)Slijepcevich, Walt (Mar, No. 3, pg 67)Smith, Winter J. (May, No. 5, pg 106)Sohl, Henry (SI, pg 14)Spence, Ann (Sep, No. 8, pg 177)Squyres, Steven (SI, pg 20)Waggener‚ Jeanne (Apr, No. 4‚ pg 70)Walker, Mary (Oct, No. 9, pg 204)Wall, Donna (SI, pg 20)

Wand, Hal (May, No. 5, pg 108; SI, pg 11; SI, pg 17; Nov-Dec, No. 10, pg 216)

Wetherbee, Charles (May, No. 5, pg 108)Whitten, Mark (Sep, No. 8, pg 184; Nov-Dec,

No. 10, pg 216)Wickizer, Phil (Nov-Dec, No. 10, pg 217)Wills, David (Oct, No. 9, pg 204)Winsley‚ William T. (Mar, No. 3, pg 67; SI, pg

3; SI, pg 12; SI, pg 16; SI, pg 20)Woodberry, Penny (Sep, No. 8, pg 177)

Professional Affairs Update2011-2012 Influenza Vaccines Approved

(Oct, No. 9, pg 202)AHRQ and NCPIE Partner to Provide Pa-

tients Medication Adherence Resources (Aug, No. 7, pg 157)

Clarification (Sep, No. 8, pg 181)Clarification Regarding Pradaxa Storage

and Handling Requirements (Nov-Dec, No. 10, pg 224)

Contaminated TPN Spurs ISMP Call for Action (Jun-Jul, No. 6, pg 135)

DEA Guidance: Information Pharmacists May Provide on CS II Prescriptions (Nov-Dec, No. 10, pg 222)

DEA Policy Statement Clarifies Agents’ Roles in Communicating CS Prescrip-tions (Jan, No. 1‚ pg 19)

DEA Seeks Information for Emergency Scheduling of Synthetic Cannabinoids (Feb, No. 2‚ pg 40)

FDA Alert: Errors from Confusion Between Risperidone and Ropinirole (Sep, No. 8, pg 179)

FDA Alert Regarding Liver Injury Associated with Dronedarone (Apr, No. 4‚ pg 86)

FDA Alerts Regarding Drugs Voluntarily Re-called by Manufacturers (Feb, No. 2‚ pg 40)

FDA Asks Manufacturers to Limit Acet-aminophen Strength (Apr, No. 4‚ pg 86)

FDA ‘Bad Ad’ Program Increases Provider Participation (Sep, No. 8, pg 179)

FDA Issues Warning Regarding Benzocaine (Jun-Jul, No. 6, pg 135)

FDA, NABP Partner to Help Prevent Acet-aminophen Toxicity (Jan, No. 1‚ pg 19)

FDA, Other Regulators Fight Internet Drug Outlets (Jan, No. 1‚ pg 20)

FDA Pradaxa Storage and Handling Re-minder (Jun-Jul, No. 6, pg 135)

FDA Seeks Information on Stolen GSK Products (Apr, No. 4‚ pg 86)

FDA Seeks Information Regarding Stolen BMS Products (Feb, No. 2‚ pg 40)

*SI = Special Issue

november-december 2011

231

Index Volume 40

FDA Takes Action Against Supplements Containing Active Drug Ingredients (Mar, No. 3‚ pg 65)

FDA Updates for Safe Administration of Acetaminophen to Children (Oct, No. 9, pg 202)

FDA Warning Regarding Proper Storage of Benzonatate to Protect Children (Mar, No. 3‚ pg 65)

FDA Warns Not to Use Terbutaline in Pregnant Women (May, No. 5, pg 109)

FDA Warns of Counterfeit ExtenZe (Aug, No. 7, pg 155)

ISMP Issues Safety Alert Regarding In-sulin Preparation and Administration (Nov-Dec, No. 10, pg 222)

‘Know Your Dose’ Campaign Aims to Prevent Acetaminophen Overdose (Aug, No. 7, pg 155)

Latest FDA Drug Info Rounds Released (Jun-Jul, No. 6, pg 135)

Methylene Blue and Linezolid May Inter-act with Certain Psychiatric Medica-tions (Oct, No. 9, pg 202)

NCPDP White Paper Recommends Con-sistent Labeling for Prescription Acet-aminophen (Nov-Dec, No. 10, pg 222)

New Acetaminophen Dosing Instruc-tions (Oct, No. 9, pg 202)

New FDA Drug Info Rounds Training Video (Mar, No. 3‚ pg 65)

New FDA Sunscreen Labeling Require-ments and Proposed Rule (Sep, No. 8, pg 179)

New OTC Pediatric Pain Reliever in Con-centration (Aug, No. 7, pg 155)

New Tamper-Resistant Oxycodone Prod-uct Approved (Sep, No. 8, pg 179)

One Lot Jantoven Warfarin Sodium Tab-lets Recalled (May, No. 5, pg 109)

PTCB Reports Record Number of Candi-dates (May, No. 5, pg 109)

Role of Community Pharmacy in H1N1 Vaccination Campaign Highlighted by IOM (Feb, No. 2‚ pg 40)

Second DEA Drug Take-Back Event (Aug, No. 7, pg 155)

‘ScriptYour Future’ Provides Patients and Providers with Adherence Tools (Aug, No. 7, pg 157)

SimplyThick Product Linked to Cases of Infant NEC and Two Deaths (Aug, No. 7, pg 157)

Study Analyzes Acetaminophen-Related ER Visits (Aug, No. 7, pg 155)

Surescripts Publishes Guidance for Elec-tronic Prescriptions (Apr, No. 4‚ pg 86)

Unapproved Drugs Seized by US Mar-shals at FDA Request (May, No. 5, pg 109)

State Board NewsAL Board Code of Professional Conduct

Forbids Prescription Transfer Incentives (Nov-Dec, No. 10, pg 225)

AL Board to Allow Only ACPE-Approved CE Programs (Feb, No. 2‚ pg 41)

Alaska Board Proposes Regulation Project to Provide Medical Marijuana (Apr, No. 4‚ pg 87)

AR Law Requires Pharmacist Determina-tion for PSE Product Sales (Aug, No. 7, pg 156)

Grant Funds Sought for Drug Take-Back Program in Lincoln-Lancaster County, NE (Mar, No. 3‚ pg 66)

Idaho Board Requires Fingerprint Process-ing (Jan, No. 1‚ pg 21)

IA’s PMP Reduces the Number of Patient Prescriptions from Multiple Prescribers or Pharmacies (Nov-Dec, No. 10, pg 221)

Kansas Board Implements Statewide PMP (Mar, No. 3‚ pg 66)

Kentucky Board Reports Legislation Up-dates (Sep, No. 8, pg 180)

KS Board Highlights Patient Safety Benefits of K-TRACS (Nov-Dec, No. 10, pg 221)

KS to Track PSE Sales Electronically to Combat Meth (Jan, No. 1‚ pg 21)

Louisiana Seeks Pharmacists and Phar-macy Technicians to Join Disaster Team (Apr, No. 4‚ pg 87)

Missouri Board Releases ‘Pharmacy Prac-tice Guide’ to Support Licensees (Aug, No. 7, pg 157)

New MD Bill Changes ‘Deemed Status’ Re-quirements for Wholesalers (Jan, No. 1‚ pg 22)

New Oklahoma Regulation Blocks PSE Sales to Meth-Related Drug Offenders (Apr, No. 4‚ pg 87)

NY Board Announces Extension of Immuni-zation Law (Nov-Dec, No. 10, pg 225)

NM Board to Require Prior Registration for Technicians, Followed by Certification (Aug, No. 7, pg 156)

NM Classifies Tramadol as a Schedule IV CS (Aug, No. 7, pg 156)

OH Board Changes Rules on Serial Num-bering of Prescriptions and Prescription Copy (May, No. 5, pg 110)

OH Task Force Addresses Issues from En-forcement to Treatment (Feb, No. 2‚ pg 41)

OK Board to Convene Technician Rules Committee (Jun-Jul, No. 6, pg 133)

Oklahoma Board Approves Safe Medica-tion Disposal Pilot Program (Oct, No. 9, pg 203)

OR Board Clarifies DUR Requirements for Pharmacies (Feb, No. 2‚ pg 41)

OR’s PDMP Now Requiring Reports (Aug, No. 7, pg 156)

PDMP Advisory Board Established in AK (Jun-Jul, No. 6, pg 133)

SC Board Requires Participation in Real-Time PSE Monitoring Program (May, No. 5, pg 110)

SC Protocol Regarding Out-of-State CS Pre-scriptions Addressed (May, No. 5, pg 110)

SD Establishes PDMP (Jan, No. 1‚ pg 21)South Dakota Board New Policies Regard-

ing Changing Quantity Dispensed (Oct, No. 9, pg 203)

South Dakota Board Prepares for PDMP (Oct, No. 9, pg 203)

Temporary Rule Adds Products Found in ‘Spice’ to Idaho Schedule I CS List (Mar, No. 3‚ pg 66)

Tramadol and Carisoprodol Classified as Schedule IV in Wyoming, Tennessee (Sep, No. 8, pg 180)

Virginia Board Begins New Inspection Process for Pharmacies (Oct, No. 9, pg 203)

Virginia Board Reports Updates to its PMP (Mar, No. 3‚ pg 66)

VT Board Receives Legislative Approval to Amend Statute on Brand Certification (Jan, No. 1‚ pg 22)

WA Bans ‘Bath Salt’ Chemicals (Jun-Jul, No. 6, pg 133)

WA Board Adopts Temporary Practice Per-mit Rule (Jan, No. 1‚ pg 21)

WA Sets New Pain Management Prescriber Rules (Jan, No. 1‚ pg 21)

WA’s Health-PACT Project Fosters Com-munication to Improve Patient Safety (May, No. 5, pg 110)

WA State to Require CE for Pharmacy Technicians (Jun-Jul, No. 6, pg 133)

WA Requires Electronic Tracking of Meth-amphetamine Precursor Products (Nov-Dec, No. 10, pg 221)

Wyoming Board Notes CS Legislation Up-dates (Sep, No. 8, pg 180)

*SI = Special Issue

National Association of Boards of Pharmacy1600 Feehanville DriveMount Prospect, IL 60056

nabp newsletter

NABP 108th Annual MeetingMay 19-22, 2012

Sheraton Philadelphia Downtown HotelPhiladelphia, PA

The NABP Annual Meeting offers attendees the opportunity to assist in shaping the future direction of NABP by participating in important business sessions during which officers and members of the NABP Executive Committee are elected and resolutions are voted upon. In addition, the meeting provides Accreditation Council for Pharmacy Education-accredited continuing pharmacy education programs and networking opportunities. More information will be available in future issues of the NABP Newsletter and in the Meetings section of the NABP Web site at www.nabp.net/meetings.

Save the Date!